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ABSTRACT 
 
Insulin-Dependent Diabetes Mellitus (IDDM or type 1) is an autoimmune, 
chronic disease characterised by hyperglycaemia, resulting from an inflammatory 
infiltration of the islets of Langerhans. The selective destruction of β-cells leads to a 
lower insulin secretion from the endocrine pancreas. The mainstay treatment for IDDM 
patients is chronic insulin injection. Although insulin therapy has dramatically reduced 
mortality from diabetes, patients often incur in complications such as nephropathy, 
neuropathy, angiopathy and retinopathy. Moreover, patients are risk severe and 
sometimes fatal hypoglycaemic events. 
Pancreas transplantation is currently the only therapeutic approach to restore 
normoglycaemia and maintain long-term glucose homeostasis; moreover, this procedure 
improves patients’ quality of life.  
An alternative to the replacement of the whole pancreas is the transplantation 
of islet of Langherans cells, isolated from donor pancreata and infused into the 
recipient’s liver via the portal vein.  
Compared to solid organ transplantation, the advantages of islet transplantation consist 
in a relatively simple surgical procedure with low incidence of peri-operative risks. 
Nevertheless, the particular structure of pancreatic islets resulted in being injured after 
the isolation procedure. 
However, the recurrence of immune response after transplantation and the diabetogenic 
and growth-stunting side effects of immunosuppressants are major challenges to the 
application of islet transplantation. 
In the last decade many studies have demonstrated the efficacy of cell 
therapy either with Mesenchymal Stem Cells (MSCs) or Endothelial Progenitor Cells 
(EPCs) treatment when co-transplanted with pancreatic islets. The first type of cells 
were reported to modulate the immune response in an allogeneic transplant, preventing 
the graft-versus-host disease (GVHD) and also improving graft function in the long-
term by maintaining glucose homeostasis. The EPCs showed to have strong 
revascularization properties in several diseases, such as cardiovascular disorders, 
atherosclerosis and diabetes. 
This thesis aims to investigate the role of MSCs and EPCs in prolonging 
graft survival of pancreatic islet transplantation in a chemically induced rat model of 
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type 1 diabetes in order to prolong the graft function and reach normoglycaemic levels 
in the long-term.  
We used a rat model to investigate the effect of MSCs and EPCs in 
combination with islets of Langerhans (700 IE + 500,000 EPCs and 700 IE + 500,000 
MSCs) in a syngeneic and an allogeneic diabetic-induced rat model which underwent 
pancreatic islet transplantation via the portal vein. These types of transplants were 
compared with islet alone treatment (700 IE), either syngeneic or allogeneic. 
We obtained the reversal of the diabetic status in animals up to 6 months 
after the transplant when they had received islets and EPCs, and up to 75 days post 
transplant when they had received islets and MSC therapy. The glycaemic values were 
also confirmed by intraperitoneal glucose tolerance test measures for animals 
transplanted with IE and EPCs either in syngeneic or allogeneic models. 
From data obtained from molecular biology assays on ex vivo liver tissues 
deriving from transplanted animals, we observed that a regulation in the 
revascularization and angiogenesis genes (VEGF-A, ANG-1, PECAM-1, SDF-1) 
occurred. Thus, EPCs could act through a regulatory mechanism as shown by their 
angiogenic gene expression.     
These data suggested that both MSCs and EPCs were able to revascularize 
pancreatic islets and improve the syngeneic graft survival up to a complete healing in 
our diabetic animal model.  
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1. INTRODUCTION 
 
1.1 Diabetes Mellitus 
 
Diabetes mellitus is a chronic disease characterised by hyperglycaemia, 
which is caused by  lower insulin secretion from the endocrine pancreas or by insulin 
resistance of peripheral tissue.  
According to data available from WHO, about 346 million people worldwide have 
diabetes, in 2004 an estimated 3.4 million people died from the consequences of high 
blood sugar, and more than 80% of diabetes deaths occur in low- and middle-income 
countries. Furthermore, it is predicted that diabetes deaths will double between 2005 
and 2030 (http://www.who.int/diabetes/en/index.html). 
Two main types of diabetes mellitus are currently known: type 1 (Insulin-Dependent 
Diabetes Mellitus, IDDM) and type 2 (Non-Insulin-Dependent Diabetes Mellitus, 
NIDDM).  
The first type is an autoimmune disease that mainly affects young people 
and is  caused by the presence of an inflammatory infiltrate in islets of Langerhans and a 
selective destruction of pancreatic beta cells which provokes insulin deficiency1.  
NIDDM generally has its onset in persons of over 40 years of age; it is 
untied up to immune mechanisms and  relates to cellular insulin-resistance by peripheral 
tissues2. Furthermore, it is linked to major metabolic dysfunctions such as obesity, 
altered insulinic secretion and functionality, and also  high endogenous glucose levels. 
Insulin resistance is the basis of the disease, nevertheless high blood glucose levels 
derive from a combination of reduced insulin secretion. The latter can be due to a failure 
in β cells functionality, a chronic exposition to fatty acids and hyperglycaemia3. Type 2 
diabetes is the  most common form of diabetes mellitus as approximately 80% of 
diabetic patients are affected by NIDDM. Due to changes in human behaviour, 
increasing body mass index, obesity and life style, there is a rising incidence of the 
disease4. Type 2 diabetes develops with a minor tolerance of glucose in the blood after a 
progressive increase of insulin resistance deriving from tissues. Insulin resistance is 
balanced at the beginning of the onset by an increase in the functionality of β cells 
(from an hyperplasia of β cells) and it is subsequently characterized by a loss of the 
mass in these (the same) cells.   
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Only 5-10% of diabetic population is affected by type 1 diabetes, although it 
represents the main social and health problem. As  the disease  rapidly develops, young 
people  are mostly affected and there are long-term consequences due to serious 
complications with the cardiovascular, nephritic and nervous system5. 
Nowadays, 5 million people in the world are affected by IDDM and millions of new 
cases are being registered with severe diabetic complications. In contrast to type 2 
diabetes, IDDM is connected to chromosome 6 gene modification in correspondence of 
the Human leukocyte antigen region (HLA), responsible for gene codification of class II 
Major Histocompatibility Complex, (MHC-II), which is able to bind and present antigen 
to T-helper lymphocytes. This triggers the immunological response. In the HLA-D 
region, either DR3 or DR4 alleles in DR gene class are present in the majority of people 
affected by IDDM. The only factors that cannot lead to the income of the disease are 
genetic ones; several environmental factors, difficult to be revealed, play a key role in 
its appearance. The most probable and suspected factors are viruses, such as 
enterovirus6, rotavirus7 and rubella8. In type 1 diabetes, the genetic alteration of MHC-II 
molecules of the HLA system compromises the identification T cells-mediated; 
activated clones of T cells identify and destroy β cells with a consequent severe insulin 
deficiency. These clones are able to escape thymus check during the process of 
tolerance induction and, once released into the blood flow, can be activated and destroy 
self antigens.  
More than 30 decades ago it was observed that the antibodies directed 
against the sections of pancreatic islets were present in the serum of patients affected by 
type 1 diabetes. These antibodies were named ICA, “islet cell antibodies”, directed 
against islet cells. The main identified auto-antigens was the isoform 65 of glutamic 
acid decarboxylase (GAD65)9, the transmembrane protein that belongs to the protein 
tyrosine phosphatase family (IA-2)10 and the endogenous insulin (IAA)11. In the pre-
diabetic phase, auto-antibodies directed against islet cells, ICA, are the most useful for 
predicting the disease. In most cases, in patients who developed diabetes later, ICA 
levels were present since they were 5 years old12. This implies that the autoimmune 
process remains in a sub-clinical phase for many years and clinical signs are not evident 
until 80% of β-cells are destroyed. In the early phase of diagnosis, about 90% of 
patients affected by IDDM have a high auto-antibody level (Type 1A DM); the 
remaining 10%, who have no level of auto-antibodies in their serum, develop type 1 
diabetes in adult age, the maturity-onset diabetes of the young (MODY). This can be the 
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result of a dysfunction in β-cells with a dominant autosomic inheritance (Type 1B 
DM)13. 
Some patients affected by type 1 diabetes exhibit an insulin resistance 
typical of type 2 diabetes which can lead to neurological and vascular diseases14. There 
is an important controversial overlap between type 1 and type 2 diabetes: about 10% of 
patients affected by type 2 diabetes have a high level of auto-antibodies in the blood15. 
Long-term studies have shown that tight control of blood glucose either 
through conventional intensive insulin treatment, self-monitoring and the patient’s food 
education, significantly prevents the onset of the disease and delays the development of 
chronic complications associated with it16. Nevertheless, in these patients severe 
hypoglycaemic events can occur which, in some cases, can become fatal17.  
A new and promising approach to improve glucose homeostasis is based on 
insulin pump and insulin secreting devices, but the development of reliable glucose 
sensory technology at present remains  a limiting factor. 
 
 
1.2 Pancreas Transplantation 
 
Pancreas transplantation is at present the only therapy able to restore 
normoglycemia and maintains long-term glucose homeostasis18. The first pancreas 
transplant was performed in 1996 in combination with a kidney transplant in a patient 
affected by IDDM with terminal renal insufficiency; it proved to re-establish 
normoglycemic conditions without endogenous insulin injection. Nevertheless,  
primitive surgical techniques reported a high level of morbidity, graft difficulty and a 
low survival rate amongst patients19. Improvements in surgical techniques, the 
introduction of immunosuppressive therapies and the monitoring of rejection grade and 
organ functionality after transplantation reduced patients’ morbidity and prolonged graft 
survival20.  
Three distinctive types of pancreas transplantation have been identified: 
simultaneous kidney-pancreas transplantation (SPK), pancreas after kidney 
transplantation (PAK), in patients who have already received a kidney transplant 
because of severe renal insufficiency, and a pancreas transplantation alone (PTA). 
Different kinds of surgical approaches can be estimated with their results and risks. 
About 25,000 patients throughout the world undergo pancreas transplantation, because 
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it improves quality of life and regresses several diabetic complications21. Simultaneous 
kidney-pancreas transplantation is considered to be standard treatment for patients 
(selected on main criteria) with type 1 diabetes and end stage renal insufficiency22. 
Numerous studies show the beneficial effects on survival, quality of life and the reversal 
of further complications related to diabetes in these patients23. 
Simultaneous kidney-pancreas transplantation can indeed solve the 
metabolic and renal problem together, requiring no further treatment for insulin-
dependence and no need for dialysis treatment (also in cases where the transplant is 
executed before entering into the dialysis). Another advantage is that possible rejection 
can be diagnosed early related to functional and structural modifications by the kidney. 
In this case, the right surgery is able to recover the kidney, and, above all, the pancreas.  
Though pancreas transplantation can lead to insulin independence (in the 
first year after transplantation), more than 80% of patients who have received 
transplants have been exposed to numerous and severe post-operative risks due to the 
complexity of surgical methodology24, such as graft vessel thrombosis, intra-abdominal 
haemorrhages, graft organ pancreatitis, and pancreatic fistulas development etc., 
requiring subsequent laparotomy and producing further graft loss. As a matter of fact 
some aspects of pancreas transplantation have to be improved, such as the role of 
surgical procedures, the selection criteria of the recipients, the correct 
immunosuppressive therapy and the individual impact of both metabolic and genetic 
immunological factors on survival and graft functionality. 
Post-operative complications limit the wide diffusion of pancreas 
transplantation, which is a surgical procedure with high morbidity and occasional 
mortality25. 
Because of surgical-related risks and immunosuppressive treatment, 
pancreas transplantation is limited to patients affected by type 1 diabetes with severe 
clinical complications; in such cases the severity of the disease justifies the risks related 
to the transplant procedure. Finally, pancreas transplantation is not considered a valid 
alternative for young patients who do not have apparent complications.    
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1.3 Rejection and immunosoppressive treatment within pancreas transplantation 
 
In order to avoid the functional deficit of a living organ, patients are exposed 
to organ transplantation. 
Transplantation is a procedure involving cells, tissues or organs sampling 
from an individual (donor) with the graft being re-transferred to a different one 
(recipient). Based on both donor and  recipient identity, the following types of 
transplantation can be identified: 
Autotransplantation: the transfer of graft tissue from one part of the body to another in 
the same individual; 
Isotransplantation: organs or tissues from a donor are transplanted in a genetically 
identical recipient (i.e.homozygous twin);  
Allotransplantation: the  most common clinically performed transplant whereby a donor 
gives an organ to a genetically different recipient; 
Xenotransplantation: a tissue or an organ from a donor is transferred to a different 
species recipient (maximum genetical variability). 
The introduction of a foreign organ or foreign tissue into the organism can 
lead to the development of rejection, due to the recipient’s immunological system 
identifying the graft donor tissue as foreign cells which either give a humoral or cellular 
response, with consequential graft loss. The intensity and time required to verify a 
rejection grade depends on the donor and recipient genetic compatibility. If there is 
perfect compatibility (auto- or iso-transplantation), no rejection grade will develop. 
Furthermore it is compulsory to prevent rejection infiltration by selecting the best donor 
possible and the right immunosuppressive treatment. 
Several rejection grades have been classified according to the 
histopathological characteristics and the time gap between the operation and the onset of 
rejection. 
Hyperacute rejection focuses on haemorrhage and vessels thrombosis: it begins in the 
early minutes after transplantation, particularly after donor vessel anastomosis with 
recipient vessels. This causes the host’s preformed circulating antibodies to bind to the 
antigens expressed on endothelial cells of the graft.  
This link activates the complement system with further alterations on graft 
vessel walls, thus favouring the development of vessels thrombosis. Endothelial cells 
have been induced to secrete high molecular weight types of vonWillebrand factor, 
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which are able to mediate adhesion and platelet aggregation. All of these phenomena 
contribute to thrombosis and vessel closure and graft tissue also has an irreversible 
ischemic impairment. Hyperacute rejection is mainly due to G immunoglobulin, IgG, 
which has turned into proteic alloantigens due to the development of foreign MHC 
molecules after a blood transfusion, prior to the graft procedure or repeated pregnancies. 
If their levels are low, the phenomenon develops slowly, over several days, before 
establishing itself. 
Acute rejection occurs one week after transplantation mediated by T lymphocytes, 
macrophages and antibodies inducing parenchymal or vascular impairment.   
The delayed onset of this type of rejection is due to the time required for T 
effector lymphocytes to differentiate themselves and for the production of antibodies to 
mediate the reaction26, 27. They can induce the direct lysis of grafted cells or cytokines 
production by recruiting and activating inflammatory cells responsible for tissue 
necrosis28. Acute rejection appears in vascularized grafts, just as in kidney grafts, 
mediated by CD4+ and CD8+ lymphocytes often detected by acute inflammation 
through the microvasculature: the first targets of this process are endothelial cells29. The 
graft infiltrate present in acute cellular rejection is mainly made up of graft alloantigens 
specific CD8+ T cells30. CD4+ T lymphocytes can exert their role through cytokines 
production and the induction of a delayed type hypersensitivity (DTH) reaction; these 
cells alone can induce an acute rejection31.  
Over a long period of time a chronic rejection is characterized by graft tissue 
fibrosis with normal structural loss32. Nowadays the “graft arteriosclerosis” or 
“accelerated arteriosclerosis” is recognized as the main cause of graft failure and 
appears as an arterial vessel occlusion due to smooth muscle cell proliferation of the 
intima vessel. This condition is an expression of a delayed hypersensibility reaction in 
the organ parenchyma where lymphocytes, activated by alloantigens expressed on 
endothelial cells, induce macrophages to secrete growth factors to smooth muscle cells. 
Therefore, macrophages activation and subsequent mesenchymal stem cell growth 
factor production, just like platelet-derived growth factor (PDGF) which stimulates 
proliferation of fibroblasts and synthesis of collagen, are typical fibrosis-based rejection 
grade factors. Without the right immunosuppressive treatment, the transplanted organ 
gives rise to increasing impairment mediated by the recipient’s immunological system.  
In the last forty decades, the development of immunosuppressive drugs have 
changed solid organ transplantation (the kidney, heart, lung, liver and pancreas) into a 
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clinical routine procedure. Increased short-term graft survival is due to better rejection 
prevention and its more efficacious treatment in cases where the process appears.   
Immunosuppressive treatment can induce its effects by acting through the 
activation of T cells, cytokines production or clonal espansion. Immunosuppression 
standard protocols consist of early therapies and maintenance to prevent acute rejection 
and predict short cycles of more aggressive therapies for the treatment of further acute 
rejection events.     
 
1.3.1 Early immunosuppression 
 
Very strict immunosuppressive protocols are applied in the immediate post-
operative days when the grade of rejection is at its maximum. Most patients’ initial 
therapy consists of high drug doses used in maintenance therapy, even though in some 
cases potent antibodies anti-T cells are administered. The latter protocol is mainly used 
in subjects with higher risk of acute rejection (children, sensitive patients who have had 
previous transplants and transfusion or multiple pregnancies).     
Standard induction therapy consists of a 7-14 days cycle with polyclonal 
anti-lymphocytes antibodies or anti-CD3 antibodies. These drugs successfully decrease 
the incidence of acute rejection and its extent, though their long-term use is not advised 
since they can increase severe infections and malignancies.     
In early therapy, the efficacy of several clinical trials has shown that some 
human monoclonal antibodies (basiliximab, daclizumab) are active towards interleukin-
2 receptor (IL-2) on T cell activated surfaces, whose inhibition causes a specific 
immunosuppressive effect. 
 
1.3.2 Maintenance therapy 
 
The immunosuppressive state of maintenance in grafted patients can be 
achieved by the right combination of immunosuppressive drugs. This protocol reduces 
side effects and blocks several molecular mechanisms involved in T cells activation. 
The standard combination is generally made up of corticosteroids, calcineurin 
inhibitors and antiproliferative agents. 
Transplant characteristics such as donor/recipient HLA compatibility rate, 
the organ to be transplanted and the patient’s state of health, all influence the choice of 
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and doses of immunosuppressive drugs. Actual immunosuppressive protocols, used in 
pancreas transplantation require a combined use of drugs: tacrolimus and 
mycophenolate mofetil in 80% of cases or cyclosporine and mycophenolate mofetil in 
20% of cases. Cyclosporine and tacrolimus belong to calcineurin inhibitors; they both 
bind to cytoplasmatic receptors (cyclophyllin and FKBP-12) and resulted as 
calcineurin-inactivating complexes, a T cells receptor signalling pathway enzyme, 
preventing the IL-2 gene transcription and relative T lymphocytes-dependent activation.  
The introduction of Cyclosporine A in graft treatment has significantly increased graft 
survival even though the drug has severe side effects such as acute and chronic 
nephrotoxicity, hypertension, hepatotoxicity, neurotoxicity and hyperlypidemia etc.33.  
In order to minimize cyclosporine toxic effects and at the same time maintain an 
adequate immunosuppressive effect, its dose has to be monitored and personalized for 
each patient.  
Tacrolimus is a highly nephrotoxic, neurotoxic and diabetogenic drug, but in 
response to cyclosporine it reduces hypertension, hyperlipidemia, hirsutism and gingival 
hypertrophy cases34.  
Mycophenolate mofetil is a micophenolate semisinthetic acid derivative, 
which acts through the de novo selective synthesis block of purins and several 
lymphocytes responses; among the various collateral effects, severe gastrointestinal 
outcomes and an increasing infectious risk by cytomegalovirus were present.   
The combination of tacrolimus and mycophenolate mofetil has largely 
substituted that of cyclosporine and mycophenolate mofetil due to evidence of a 
rejection grade reduction and minor side effects. 
The use of sirolimus in different concentrations, in association with other 
immunosuppressants has led to great advantages in grafted patients. 
Sirolimus (Rapamycin) is an immunosuppressive drug which is able to inihibit T cells 
response towards cytokines stimuli, by blocking IL-2 receptor intracellular signalling 
and inhibiting T lymphocytes development. Sirolimus binds to the same intracellular 
protein over which the tacrolimus acts (FKBP-12) and is often used together with 
tacrolimus or cyclosporine. Its use can reduce an associated drug quality with a 
consequent decrease in side effects.  
Among the various drug combinations, tacrolimus/sirolimus is the most 
frequent, followed by sirolimus-cyclosporin, tacrolimus-sirolimus-mycophenolat 
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mofetil and mycophenolate mofetil-sirolimus; sirolimus is used alone in only very few 
cases35. 
In some transplant centres, corticosteroids continue to be used in 
immunosuppressive treatments but in most cases it has been a real challenge to turn 
towards drug free protocols in order to minimize glucose intolerance, dyslipidemia and 
osteoporosis.  
Calcineurin inhibitors can also show these side effects, including the β-cell 
damage within islets because of apoptosis36. Recent times have seen an increase of 
patients treated with antibodies, mostly those receiving a non-combined pancreas 
transplant or simultaneous kidney-pancreas transplant37. In 90% of cases the treatment 
entails a combination of several antibodies but occasionally just one alone is used38. 
The most involved anti-lymphocytes agent is the monoclonal antibody 
OKT3, together with polyclonal treatments, such as anti-thymocyte globulin (ATG). T 
anti-lymphocytes antibodies treatment (monoclonal or polyclonal) can begin 
immediately after the post-operative period or  during the pre-operative protocol in 
order to create an immunoprotective condition within the organism. 
 
 
1.4 Pancreatic islet transplantation 
 
The islets of Langerhans are a promising alternative to whole organ 
transplantation; they are collected from a donor’s pancreas and injected through the 
portal vein into a recipient’s liver (figure 1). 
 
Figure 1. Islet transplantation. Islets were purified and infused via the portal vein of diabetic recipients, 
once they were extracted and isolated from the pancreas. 
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In 1893 the English surgeon W.Williams attempted to transplant the extract 
of sheep pancreas into a 15-year-old boy with a severe form of diabetes, marking  the 
first pioneeristic xenograft transplant39. 
More than 50 years later, in 1967, Paul Lacy suggested that a better solution 
to exogenous insulin treatment was the transplant of pancreatic islets40. Later, in 1972, 
Lacy successfully reversed diabetes for the first time in a murine model of chemically 
induced diabetes through a pancreatic islet infusion41.     
It was only in 1986 that an automated method for islet isolation with a 
sufficient number of islets to be transplanted was introduced into the clinical setting, 
and in 1989 the Paul Lacy group exploited this method to reverse diabetes and obtain 
insulin independence after human islet transplantation42. Unfortunately the graft failed a 
few days after surgery, perhaps due to an inadequate immunosuppressive regimen. 
Until 1990, none of the above-mentioned transplants were successful until 
the group from Pittsburg, USA, performed the first series of human islet allograft, 
prolonging insulin independence through steroid-free immunosuppressants treatment 
(FK506). The patients remained insulin independent up to 5 years after the transplant. 
The long-term survival of intrahepatic human islets was confirmed by liver biopsies, 
revealing that allogeneic human islets were successfully engrafted in the hepatic 
microenvironment43. 
In 1996 in Giessen, Germany, there was an improvement in peri-transplant 
management as well as the immunosuppression results in 100% initial islet-graft 
function and 40% insulin independence after one year. 
In 1999 a very successful protocol was achieved in clinical trials by the 
Edmonton group which combined islet transplantation with the use of Rapamicyn by 
implementing a steroid-free protocol. The result was a series of transplants with insulin 
independence in 7/7 human islet-cell transplant recipients within the first year44. All 
patients received pancreatic islets from 2 donors (only in one case 4 donors were 
necessary). The Edmonton protocol used a combination of immunosuppressive drugs, 
including Daclizumab (Zenapax), Sirolimus (Rapamune) and Tacrolimus (Prograf). 
Daclizumab was given intravenously right after the transplant and then discontinued, 
while Sirolimus and Tacrolimus, the two main drugs that maintain the immune system 
preserved from the destruction of the transplanted islets, must be administered 
throughout the patients’ life44.  
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The difference between the Edmonton protocol and previous ones was a 
convenient number of high purity level islets, but, most of all, a less diabetogenic and 
steroid-free use of immunosuppressive drugs.  
Islet Transplant Registry reported more than 450 allogeneic pancreatic islet 
transplantations between 1974 and 1999 in patients affected by type 1 diabetes, but less 
than 10% reached insulin independence within one year, though 28% of patients 
secreted high levels of C peptide. Several factors contributed to the failure, such as a 
poor transplanted islet mass, inadequate anti acute rejection treatment, diabetes 
autoimmune recurrence and extremely toxic immunosuppressive drugs such as 
cyclosporine and glucorticoids. The clinical introduction in the Edmonton protocol led 
to progress in pancreatic islets transplantation, with the general acceptance of islet 
transplantation as a feasible clinic therapy, especially for the treatment of patients 
affected by type 1 diabetes with developed frequent hypoglycaemic episodes.  
A further study in the University of Alberta on a 66-year-old patient showed 
that 82% of patients who received a transplant remained insulin independent up to one 
year after transplantation; this percentage decreases as the years go by: up to 70% in the 
second year and 50% in the third year. In spite of this, many patients continued to 
produce sufficient amounts of insulin in order to reduce hypoglycaemic risky episodes; 
therefore, islet transplantation mostly became efficacious in glucose level control. 
Similar results were produced by other studies involving islets which were kept in 
culture before transplantation up to three days (2001, Miami, USA).  
The National Institute of Health, Immune Tolerance Network (ITN) set up a 
multicentre trial of islet transplantation. The Collaborative Islet Transplant Registry 
(CITR) was established in 2001 by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK).  
The Registry was created with the aim of collecting, analyzing and 
comprehensively communicating data from all islet/beta cell transplantation centres in 
the US, Canada and some European and Australian centres to guide transplant centres in 
developing and refining islet/beta cell transplant protocols.  
A close network of collaboration between initiatives and programs of the 
National Institutes of Health, the Juvenile Diabetes Research Foundation International 
(JDRFI) and other health centres, such as the Health Care Finance Administration-
HCFA, the Health Resources and Services Administration (HRSA), and the Food and 
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Drug Administration (FDA), ensure that the outcome measures used by CITR are 
appropriate, standardized, and relevant.  
The last annual scientific report, specifically 2010 CITR (7th) Annual Report, 
presents data from the past ten years, namely the large majority of the islet transplant 
programs active in 1999-2009 (www.citregistry.org). The following data refer to the last 
decade and shows that 571 allogeneic islet transplant recipients (481 islet transplant 
alone, 90 islet after or simultaneous kidney) received 1,072 infusions from 1,187 
donors. The mean age of recipients who received an islet allograft transplant rose from 
42 to 49 years and the mean duration of diabetes grew from 26 to 32 years over the 
decade. The donors, on the other hand, rose from 42 to 44.8 years of age; about 58% of 
them were male, deceased due to cerebrovascular accidents/strokes. 
The pancreas were processed better and faster; in addition the islet product 
showed that the mean total IE rose from 417 to 463 per infusion and the β-cells growth 
amount from 217 to 335. Nevertheless, the immunosuppressive regimen revealed a 
change only using IL2R antagonists to a replacement or supplementation including T-
cell depletion with or without TNF antagonist in over 80% of the transplants in the last 
three years.   
The maintenance of the immunosuppressors was achieved by a calcineurin-
inhibitor and a combination of inosine monophosphate dehydrogenase-inhibitor 
(IMPDH). The overall results demonstrate that there is 65% of insulin independence in 
the first year post-infusion, increasing up to 75% by the second year. Moreover the 
long-term graft function significantly improved, i.e. in 2004-2007 the insulin 
independence lasted for a longer time than in 1999-2003. By observing the global data 
of CITR, it can be concluded that over the last decade the allograft recipients exhibited 
benefit with relatively low risks, (low levels of infusion-related complications, few 
events of immunosuppressors-related cancer and death), and islet transplantation was 
engrafted in recipients over 35 years of age with good glycaemic control. Finally, the 
use of vaso suppressors and insulin in the donors, as well as the use of T-cell depletion 
and calcineurin-inhibitors for immunosuppressive maintenance in the pre-operative 
period, create the best conditions for obtaining improved outcomes 
(http://www.citregistry.org/).   
Islet transplantation offers various advantages compared to the whole organ 
transplant, such as the fact that it is a relatively simple surgical procedure (mini-invasive 
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surgery) with consequent low post-operative risks and low morbidity as well as 
culturing or cryopreserving islets.    
The protocols used to handle pancreatic islets for reducing their 
immunogenicity revealed that a short time of culture was adequate. Furthermore, this 
allows the recipient’s conditioning to be optimized, with a consequent easier tolerance 
induction, and less  risk of rejection. In addition, the requirement for 
immunosuppressive drugs treatment was low45.  
Islet transplantation is indeed considered a promising strategy for the 
treatment of diabetes mainly in young patients and children with no evident insurgence 
of severe complications (i.e. when possibility of whole organ transplant has been 
discarded)46.  
There are some key points to consider in order to perform a successful 
human pancreatic islet transplant:  
- correct islet handling in pre-transplant phase: the cold preservation of the pancreas 
before islet isolation has to be less than 8 hours. The same procedure has to be executed 
in as little time as possible in order to obtain maximum yield from a single pancreas and 
preserve the vitality of the mix to be transplanted47. 
- correct number of grafted pancreatic islets: to assess an intervention with a good 
probability of success, at least 12,000 IE/Kg should be transplanted into a recipient (IE 
is Islet Equivalent, islet volume converted into the number of islet with a diameter of 
150 μ). 
On average, a human pancreas contains 300,000 to 1.5 million pancreatic islets and it 
has been evaluated that only 60% is necessary to maintain a normal glucidic 
metabolism48.  
Nevertheless, at least 2 donors are required in order for pancreatic islets to 
obtain an insulin independence, but occasionally the same result has been obtained by 
collecting islets from a single donor49. 
- ischemic and nonfunctional processes which can hit transplanted islets: islets have a 
characteristic microvasculature in a normal pancreas: arterioles are dispersed in 
capillaries in the centre of the islet, emerge through the islet peripheral area and then 
drain into the portal system (insulo-acinar portal system)50. This structure is destroyed 
after the isolation of the islets and their transplantation. During the isolation and culture 
of the islets, the endothelium loses its differentiation and is able to degenerate.  
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A rapid revascularization is required to let the islets survive and function 
after transplantation51. Therefore, the survival of grafted islets most of all depends on 
endothelial cells and capillaries originating in the implanted organ which creates the 
new vascular system of the islets. It also has to be considered  that the early ischemic 
period significantly damages the islet centre, which contains the great part of the insulin 
secreting β-cells52. 
It is known that blood vessels inside the transplant begin to be visualized 3-5 
days after transplantation, and 7-14 days after transplantation a normal blood flow is re-
established. 
- adverse effects of actual immunosuppressive protocols: immunosuppressive drugs are 
essential to prevent the processes of rejection linked to transplantation, even though 
immunosuppressive protocols based on the use of corticosteroids, cyclosporine and 
tacrolimus (FK 506) are far from being effective in islet transplantation, because the 
same drugs can induce diabetes33. 
The potential inefficacy of human islet transplantation could be linked to an inadequate 
number of grafted IE and to technical factors linked to isolation that reduces the vitality 
and functionality of the islets47. 
Moreover, the presence of non-specific inflammation and the onset of 
rejection processes53 mediated by the immune system can lead to the destruction of 
grafted islets.  
Despite increasing interest in this technique, its clinical application remains 
limited mainly because of low yield in islet achievement and side effects associated 
with the immunosuppressive drugs used. Grafted islets appear to have a greater aptitude 
towards acute rejection to verify autoimmune relapse compared to the whole pancreatic 
organ transplantation54. In the immediate post-operative period, a loss in grafted islets 
occurs55; in animal models grafted islets are about 50% less than transplanted ones. 
Moreover, it has recently been observed that patients treated with Edmonton 
protocol occasionally reached graft tolerance due to the homeostatic expansion of 
autoreactive memory cells which are able to induce rejection56. Though tolerance 
induction can be induced by using mycophenolate mofetil, the risk of normal growth 
blockage and child development57 prevent its use, except for cases in which children 
risk losing their lives because of organ insufficiency or other severe complications due 
to diabetes58. As a consequence, several aspects of islet transplantation have to be 
defined in order to introduce this clinical therapy as a routine cure which is valid for the 
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treatment of type 1 diabetes. Graft survival needs to be improved and side effects linked 
to the use of immunosuppressive drugs avoided59, by introducing new therapeutic 
strategies.  
Several approaches have been proposed in order to induce tolerance instead 
of administrate immunosuppressive therapy. These alternatives consist in the infusion of 
stem cells60 or bone-marrow cells61 or mesenchymal stem cells62 in the pre-transplant 
phase. 
 
 
1.5 Islets of Langerhans 
1.5.1 Architecture of Pancreatic Islets 
 
The islets of Langerhans are the regions of the pancreas or micro-organs that 
contain at least four types of endocrine cells: α-cells that produce glucagon, β-cells that 
produce insulin, δ-cells that produce somatostatin, PP-cells that produce pancreatic 
polypeptide, and ε-cells that produce ghrelin.  
In rodent models the distribution of these cells in the islets is not 
randomized, but β-cells are located in the inner core of the islets, while the non-β cells 
form the mantle region. This spatial position within the islets contains several properties 
so that when insulin secretion is decreased, the organization of islet cells is found to be 
changed; for example β-cells are bound with non-β-cells63. Since the non-β-cells which 
are in contact with β-cells show no increase in insulin levels in vitro studies, it is 
important to observe the that the mantle position of non-β-cells is pivotal for insulin 
regulation by homologous contacts between β-cells64. 
Scientific literature provides evidence that there is no clear agreement on the 
architecture of human pancreatic islets and their distribution, even though it is accepted 
that the endocrine components between humans and rodents are not that different and 
that β-cells are less numerous in humans than in rodents65. 
In 1976 Orci and Unger located α- and δ-cells of the human islets in the 
mantle and grouped against capillary walls within the core of β-cells63. Later Grube 
proposed that β-cells are located in the islet core and α-cells are arranged at the 
periphery and along intraislet capillaries66. 
During the past three decades it has been a great challenge to identify the 
distribution of pancreatic islets, but Bosco and his colleagues have recently proposed a 
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model showing human islet cells distribution in a trilaminar plate (a sandwich 
structure), where α-cells are in the external layers and β-cells in the internal ones. He 
also reported no vascular channel in the β-cells in the centre of the structure, but a 
vascular network was observed at the α-cells level67, (figure 2).  
         
 
 
 
 
 
 
 
 
Figure 2 Endocrine cell and vessel organization in human islets. A: α-Cells (green) reside at the 
periphery of the plate in close contact with vessels (blue). β-Cells (red) reside in the central part of the 
plate and the developed cytoplasmic extension runs between α-cells reaching the vessels surface. B: The 
plate with adjacent vessels is folded so that it forms an islet. (Bosco D., Diabetes, 2010) 
 
 
1.5.2 Physiological site for pancreatic islet transplantation 
 
Recent work by Merani and his colleagues extensively discussed the main 
role of the site of infusion by means of an animal model and human clinical practice68. 
Since the liver has been widely studied and has the advantage of a double arterial and 
venous vascular supply, many of the islets are lost during or immediately after portal 
vein transplantation. Moreover, the oxygen tension of the parenchyma is lower than that 
of the pancreas and the liver as a site of implantation is associated with procedure-
related complications, including haemorrhage and thrombosis. Patients remain insulin 
independent immediately after the surgical approach, but the effect is not long lasting69. 
Many efforts were made to achieve the best sites for pancreatic islet 
implantation in order to optimize the engraftment and function of the islets, reduce the 
number of transplanted islets and decrease immunogenicity. 
Islet milieu requires a direct access to oxygen, glucose and other metabolites 
and need to be free from toxic metabolites and oxygen free radicals. The slow 
revascularization of the transplanted pancreatic islet is another key issue and is required 
to have a good vascular supply and high oxygen levels70. The insulin hormone, which is 
 
 
A B
 23
released by β-cells, should be delivered through the portal vein, as the liver and muscle 
are primary sites of insulin action, therefore it could be beneficial to transplant the islets 
in a site that is drained into the liver71. 
In addition it is conceivable that the implantation site should be 
immunoprivileged, thus the pancreatic islets should be infused in a minimal 
inflammatory reaction site to increase long-term survival and the loss of β-cells should 
be minimal. Moreover, the implantation site should have easy access to reduce further 
complications, and the number of islets should be minimal in order to have the lowest 
transplant volume for multiple donors72.  
Merani also reported that the advantages of portal vein infusion of islets of 
Langerhans were the simple way of injecting them by cannulation of a mesenteric 
venous tributary during laparotomy or percutaneously using fluoroscopic and 
ultrasonographic guidance, and also the low requested number of islets73. At the same 
time, the intraportal site reflects that a reduced function of islets in a model without 
allorejection and autoimmune diabetes is not suitable for long-term function74. What is 
more, the instant blood-mediated inflammatory reaction (IBMIR) remains crucial in 
order for the β-cells to function after transplantation into the vascular site.  
The kidney subcapsular site is most commonly used in rodent models and 
has good results in that diabetes is reversed within a few days. The metabolic 
engraftment and function of human fetal islet-like clusters transplanted into 
immunodeficient nude mice under the kidney capsule is better than the lung, liver and 
spleen from both a morphological and functional perspective75. The disadvantage of the 
kidney capsule is the scanty blood supply that leads to a low-oxygenated 
microenvironment for the islets.  
Literature provides evidence that only 250 syngeneic subcapsular islets are 
required for the subcapsular site to reverse streptozotocin-induced diabetes in mice a 
considerable amount less compared to the 600–800 required for the intraportal site76.  
Besides the best preserved structure of rodents compared to human islets, it is not easy 
to lift or infuse islets under the rodent kidney capsule. Finally, the surgical site is very 
invasive and co-morbidities in the animal recipient population, including diabetic 
nephropathy, may reduce the hospitality of the kidney.  
The spleen, which is a metabolically suitable site for islet transplantation, is 
an alternative site but it is not as advantageous as the liver. Indeed, there are several 
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risks of haemorrhage and the improved access of lymphocytes to transplanted tissue in 
the spleen makes this site unsuitable for islet transplantation77. 
Merani investigated other main sites for pancreatic islet transplantation. The 
pancreas is in theory a good site for supporting the function of the islets in the long-term 
because of the high partial pressure of oxygen in the tissue. On the other hand, the 
relatively invasive nature of the isolation procedure and known evidence regarding the 
autoimmune recurrence of type 1 diabetes make the pancreas a clinically irrelevant site 
for transplantation68. 
Moreover, several papers showed that the intraperitoneal and omental pouch 
sites are attractive as they provide a large implantation volume and the concurrent use of 
transplant devices or capsules78. As well as its simple surgical approach, the omentum 
offers other advantages79, but the large number of islets required for both intraperitoneal 
and omentum sites and reduced data on long-term survival make these two sites less 
attractive than others. 
Islet transplantation has also been performed into bone marrow of non-
diabetic rats and in the os femoris in diabetic ones: results reported that there is a 
persistence of insulin up to 21-30 days post-transplant80. On the other hand, the 
intramuscular site is very attractive due to its simple accessibility and monitoring, even 
though this site is associated with a higher frequency of  leucocytic infiltration  
compared to others81. Another site for islet transplantation was the fat pads in the mouse 
model that showed a simple way of infusion, which was similar to the intramuscular one 
because of the low required islet number82. 
Finally, some immunoprivileged sites, such as the brain, thymus and testis83, 
were reported because they have shown to confer protection to an allotransplant and 
these sites are more suitable for transplants of cells. Indeed, they can protect the 
organism from allorejection or xenorejection without further immunosuppressive 
therapy.  
In conclusion, further research in humans is required before the adoption of 
any clinical routine, so the careful evaluation of five criteria is suggested (the cellular 
physiology of the site, the endocrine function for good glycaemic detection, the 
immunological role of the site, surgical and technical complications due to the chosen 
site and supporting evidence from studies on large animals) before choosing a clinical 
application for the alternative site for islet transplantation, even though it is actually 
indicated that the portal vein remains the main method of infusion68.  
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1.5.3 Murine models of islet transplantation 
 
A strategy to reduce the graft islet mass for transplantation to a recipient has 
been investigated in a rat model of islets transplantation. Hara et al has demonstrated 
that animals transplanted with 1500 syngeneic or allogeneic islets in the portal vein or 
under the kidney capsule restored to normoglycemia one day after transplantation. The 
authors reported no significant difference in loss of graft function between syngeneic 
and allogeneic islet transplantations during the three days after transplantation, neither 
did they observe any significant difference in deterioration of graft function between 
portal vein or kidney capsule sites of transplantation84. 
Cornolti has recently investigated whether syngeneic islet transplantation 
can obtain adequate islet function during glucose stimulation by employing a 
continuous glucose monitoring system in the diabetic rat model. Islet encapsulation 
through immunoisolation systems requires no further immunosuppressive treatment, 
thus leading to a new clinical approach. Cornolti’s group has developed two  types of 
islet transplantation: islets immunoisolated in microcapsules inserted in the peritoneal 
cavity and free islets inserted under the kidney capsule. They observed an homogeneous 
state of normoglycemia after the two protocols, but the microcapsulated one obtained a 
better control of glucose sensing and insulin release.  
Even though encapsulated islets are separate from the microcirculation with 
this method, islets can react to high glucose levels in the blood and efficiently release 
insulin. On the other hand, islets transplanted beneath the kidney capsule showed less 
viability and function, concluding that despite being nearer to the microcirculation, the 
host cell reaction was involved85. 
 
1.5.4 Clinical outcomes of islet transplantation 
 
In order to perform human islet transplantation in patients affected by type 1 
diabetes, the required clinical indications for hypothetical subjects should be the onset 
of frequent and severe hypoglycemic events. Moreover, other possible required 
indications should be severe clinical problems associated with the use of exogenous 
insulin therapy and an unsuccessful insulin-based therapy to prevent acute 
complications.  
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As reviewed by Fiorina et al., the patients that could undergo islet after 
kidney transplantation were subjects with an end-stage renal disease who also received a 
kidney transplantation alone or who rejected the pancreas after simultaneous kidney–
pancreas transplantation; otherwise, for islet transplant alone, numerous patients should 
have to be selected86. 
Data collected by the CITR revealed that 80% of graft function was 
successful at 1000 days of follow-up for islet after kidney transplantation, while for islet 
transplantation alone almost 60% at 1000 days were considered successful86. Several 
articles reported insulin independence and normalizing glucose homeostasis after an 
islet transplantation, but only few patients maintained insulin independence in the long 
term with sustained C-peptide secretion87. 
Since insulin is secreted by intrahepatic tissue in grafted patients and cleaved 
by the liver, Luzi et al. reported that not only a successful islet graft returned to basal 
hepatic glucose and improved the action of insulin88, but it also achieved a loss of 
insulin independence, in most cases, by means of long-term partial islet function89. 
The positive effect of islet transplantation was also seen in the patients’ 
survival rate; data regarding the morbidity and the mortality of patients affected by type 
1 diabetes were evaluated after the transplantation protocol.  
In 2005 Fiorina performed two types of transplants in diabetic patients in an 
attempt to determine islet transplant improvement with regard to cardiovascular 
function: a kidney-islet transplant and a kidney alone transplant. The first successful 
group of patients reached long-term C-peptide secretion, whereas the second group 
showed a loss of C-peptide secretion 6 months after transplantation. The authors 
concluded that type 1 diabetic patients with end stage renal disease who received 
kidney-islet transplantation showed an improvement in aspects of cardiac function for a 
3year follow-up in comparison with the group who had received a kidney transplant 
alone90. 
According to available data from clinical trial, it is evident that stringent 
glucose control can reduce the risk of microvascular complications91, even though no 
controlled studies have clearly answered the question of whether islet transplantation 
can halt the progression of long-term diabetic complications. Apart from the difficulties 
of performing large clinical trials and also other factors, such as the differences in islet 
isolation procedures, the absence of standardized protocols and the persistence of many 
regional-based immunosuppressive approaches, the restoration of islet function could in 
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fact be protective against long-term diabetic complications, as confirmed by a few 
uncontrolled preliminary studies from Milan, Miami and other groups. Nevertheless, 
clinical complications largely remain a strong unresolved issue, since the above 
mentioned cardiovascular function should be kept under strict observation after islet 
transplantation90.  
Patients with type 1 diabetes are also at high risk for 
macro/microangiopathy. Nephropathy is also considered to be one of the most serious 
complications of this disease, even though a study on the combined effect of islet 
transplantation and immunosuppression on kidney function has shown promising 
results, which are to be confirmed, in patients transplanted with islets alone92. Finally, 
diabetic retinopathy and complications of the central nervous system have been recently 
investigated by using islet transplantation as an improved type of treatment. 
 
1.5.5 What happens to islet structure after an islet transplantation 
 
The vasculature of islets cultured in vitro and their subsequent 
transplantation can dedifferentiate or degenerate from its original architecture. In 
addition, the immediate days after islet transplantation are critical since this process is 
characterized by substantial islet cell dysfunction and β-cells death – a more 
pronounced characteristic in diabetic recipient55. The blood flow of the transplanted 
islets seems to be lower in diabetic recipients and could be caused by an altered 
regulation of the blood flow rather than a defect in the revascularization process93.  
Furthermore, islet hypoxia is generally thought to be the major reason for the 
vulnerability of islets in the first few days of engraftment. In 1998 Carlsson 
demonstrated that oxygen tension immediately after islet transplantation was 50% of 
that in native islets and slightly lower than that in the adjacent renal cortex. One month 
after implantation, the exact time when revascularization is likely to be complete,  
oxygen tension in transplanted islets was lower than after one day. Although the newly 
born microvessels within the graft are responsible for oxygen transportation, they have a 
reduced ability to transport oxygen to the islet graft compared to the highly specialized 
vascular network of the endogenous islets. This means that transplanted islets are 
exposed to an environment containing a much lower concentration of oxygen compared  
to the native pancreas94. 
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Another major issue concerns islet vascularization after their implantation. 
Islets have less blood flow than surrounding pancreatic exocrine tissue, greater vessel 
density with greater volume, and intra-islet capillaries are lined by fenestrated 
endothelial cells95. Indeed, the revascularization of transplanted islets begins within 2–4 
days and is completed within 14 days after transplant96.  
In various implantation sites it has been observed that grafted islets have 
reported a decreased vascular density compared to endogenous ones one month after 
transplantation. In islets implanted into the spleen, as opposed to islets implanted into 
the liver or kidney, a more pronounced decrease in vascular density is well established, 
suggesting that the revascularization of transplanted islets is impaired, at least 
quantitatively, regardless of the implantation site. On the other hand, a large number of 
blood vessels was found in the connective tissue surrounding the renal subcapsular and 
intrasplenic islets, so that the predominant location of capillaries in the connective tissue 
stroma is the immediate vicinity of the endocrine tissue97. This structure was later 
confirmed by a pancreatic islet graft under the renal capsule rat model where a 
lymphatic network was shown from one week up to 9-12 months after transplantation, 
with a major number of capillaries within the connective tissue stroma between the 
transplanted islets98.  
The survival of islets in the graft depends on the diffusion of nutrients and 
oxygen99 from the surrounding tissue until the revascularization process of the grafts is 
complete. A part of the revascularization process is likely to depend on the hypoxic 
activation of genes encoding for angiogenic factors, which lead to new blood vessel 
formation and improved oxygen delivery100. 
An array of peptides including acidic fibroblast growth factor (aFGF), basic 
acidic fibroblast growth factor (bFGF), tumor growth factor- (TGF) α, TGF-β, PDGF, 
hepatocyte growth factor (HGF), tumor necrosis factor- (TNF) α, vascular endothelial 
growth factor (VEGF), angiopoietin (ANG) and interleukin- (IL) 8 were supposed to be 
the regulators of angiogenesis101. Among these angiogenic factors, the most potent 
hypoxia-inducible gene that regulates blood vessel growth has been demonstrated to be 
VEGF, a selective mitogen for endothelial cells in vitro able to promote also vascular 
permeability in vivo. VEGF is also expressed by pancreatic islets102. A study on VEGF 
gene expression carried out by Vasir et al. has shown a different pattern on 
normoglycaemic and diabetic animals after an islet transplantation in the first few days 
after transplantation. They found a slight increase in the VEGF receptor expression at 
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days 3 and 5 in the normoglycemic recipients and, at the same time, a decrease in VEGF 
expression; the beginning of angiogenesis in the grafts could be responsible for this 
trend. On the contrary, VEGF receptors in the diabetic group at days 5, 7, and 14 
showed a marked expression, perhaps in accordance with the concept that 
vascularization of transplanted islets is delayed by the presence of hyperglycemia, 
which derives from an increase in local oxygen consumption, as it is known that glucose 
oxidation in β-cells increases as glucose levels rise103. 
Vasir and his colleagues also found that both VEGF isoforms in normal and 
diabetic recipients at days 1 and 3 after transplantation increased their expressions, 
suggesting that  revascularization had already begun. A parallel increase in the 
expression of VE-cadherin was also found during the process of revascularization that 
could in part have been mediated by VEGF. Finally they reported that the diabetic 
milieu could have impaired the early vascularization of transplanted islets, thus 
providing an explanation for the less favourable outcomes104. 
More recently Golocheikine et al. have studied a model of subcutaneous islet 
transplantation in matrigel basement membrane matrix to assess the role of indirect 
proangiogenic growth factors in islet revascularization. The group has studied whether 
VEGF, a direct agonist capable of activating endothelial cell proliferation and 
migration, and HFG, a growth factor leading to a blood vessel formation in vivo besides 
inducing VEGF, could enhance graft survival and function in vivo105. A further 
confirmation of intercellular adhesion molecules (ICAM) and vascular cell adhesion 
molecule (VCAM) involvement has also suggested that a cross-talk mechanism 
between VEGF and HGF could improve the blood vessel formation toward a better 
vascularization in the graft105. 
In order to point out the importance of revascularization after islet 
transplantation, in 2006 Brissova showed that there is a reciprocal communication 
endocrine cell–endothelial cell, (figure 3), since early differentiating endocrine cells 
produced angiogenic factors including VEGF-A and ANG-1. Moreover, it was observed 
that insulin deficiency in mice with reduced VEGF-A expression was not a result of β-
cell dysfunction but an abnormality in the islet vasculature. This was in line with the 
fact that β-cells and islet microvasculature participate cooperatively in the maintenance 
of glucose homeostasis. VEGF-A was hence considered to be a key regulator of islet 
vascularization so that insulin levels in the systemic circulation could be influenced by 
modulating VEGF-A expression; this suggested that a new mechanism was able to 
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connect the impairment in islet vascularization with the defect in the release of insulin 
associated with diabetes106. 
 
 
Figure 3. Model of pancreatic islet vascularization. After an initial production of angiogenic factors 
released by early developing islet cells, a recruitment of endothelial cells and their association with 
developing islet cell clusters occurred. Next, blood flow to small endocrine cell clusters established itself 
and a concurrent organized structure of islet cell formation occurred. (Brissova M., Diabetes, 2006). 
 
 
1.5.6 Angiogenic features of intra-islet cells 
 
β-cells in mice are in direct contact with basement membranes of endothelial 
cells, whereas the intra-islet microvasculature of human islets is surrounded by a double 
basement membrane107. An extensive capillary branching in the islet core is arranged by 
one to three arterioles entering an islet.  
In this structure, the secreted hormones are forced to exit from the islet 
through small venules formed from these capillaries. The main characteristic of intra-
islet vasculature is the lining of fenestrated endothelial cells108. These fenestrae are 
thought to be induced by factors such as VEGF-A and angiopoietin-1 both secreted by 
the islet cells109. It is reported that islet endothelium induce insulin gene expression, 
stimulating β-cell proliferation and affecting adult β-cell function by secreting several 
known/unknown paracrine factors110.  
Moreover, the islet microvasculature is involved in the regulation of 
leukocyte recruitment into the islets in type 1 diabetes during the autoimmune 
destruction of β-cells. During the early phase of type-1 diabetes, islet endothelial cells 
particularly express surface leucocyte-homing receptors. These receptors can help the 
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entry of leucocytes into the islets with the consequent destruction of β-cells111. It was 
recently confirmed that the direction of blood flow within mice islets is from the inner-
outer area as well as from the top to the bottom112. This trend implicates that blood can 
flow from β-cells to non-β-cells thus involving the influence of insulin on the function 
of non-β-cells. However, in top to bottom blood flow, the cell types do not influence 
each other in any way.  
As assessed by Linn in 2003, endothelial cells contained within the islets 
required growth factors and were stimulated by FGF-2, VEGF and TNF-α to allow their 
migration. FGF-2 was indeed found to be an important factor for endothelial 
proliferation of isolated islets, while VEGF promoted a cord formation. TNF-α was 
instead able to enhance the effect of VEGF on EC proliferation. The authors 
demonstrated the significance of donor endothelial cells either in vitro as well as in vivo 
in the revascularization process. To this aim they observed that the pancreatic islet 
microvasculature  was identified as a target site for the graft rejection process. In 
addition, this structure was involved in the revascularization process since the donor 
endothelial cells remained in the graft up to 21 days after transplantation at its periphery 
and surrounded by renal tissue113. 
In order to determine whether intraislet endothelial cells participate in the 
revascularization and access the structure and composition of blood vessels in the 
revascularized grafts, Brissova et al  used a murine model in which endothelial cells 
were tagged with lacZ, which was labelled for the mouse endothelial marker PECAM-1 
(expressed on the surface of both donor and recipient endothelial cells). Brissova found 
the existence of two types of blood vessels in the revascularized mouse islet graft: 1) 
capillaries formed by either donor or recipient endothelial cells directly connected to 
each other and 2) chimeric blood vessels formed from a mixture of donor and recipient 
endothelial cells. The chimeric structure was not evident in the human graft. The 
involvement of both donor and recipient intraislet endothelial cells in the 
revascularization of transplanted islets was finally confirmed, thus demonstrating that 
those cells could integrate into the functional vasculature of revascularized islet 
grafts114. 
These data were later confirmed by Nyqvist who stated that intraislet 
endothelial cells were able to participate in the formation of functional blood vessels 
within the islet graft vasculature subsequent to transplantation. He observed that the 
transplantation of freshly isolated islets with a relevant number of endothelial cells, in 
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contrast to cultured islets, markedly improved their vascularization, thus a preservation 
of intraislet endothelial cell mass was able to improve the long-term graft function115. 
Nyqvist recently found that donor islet endothelial cells contributed to the 
revascularization process of fresh islets and they were also observed in the long-term, 
but the endothelial cells deriving from donors were not as sufficiently effective as the 
cultured islets in the reversal of diabetes116. 
 
 
1.6 Endothelial Progenitor Cells 
 
Endothelial progenitor cells (EPCs) were described for the first time by 
Asahara et al. as human adult cells involved in postembryonic neovasculogenesis117. 
Neovasculogenesis, the de novo formation of blood vessels from avascular tissue, 
differs from neoangiogenesis, the formation of new blood vessels that sprout and grow 
from pre-existing vessels. Up to Asahara’s findings it was considered that 
neovasculogenesis only occurred during embryogenesis, within the extra-embryonic 
yolk sac mesoderm, where primitive haemangioblasts arranged to form islands and 
tubular structures with further differentiation into blood and vessels118. 
The discovery of EPCs led to the new concept that vasculogenesis and 
angiogenesis could develop at the same time in postnatal life because these cells could 
differentiate into vascular endothelium, when required, through a mechanism that 
recapitulates embryonic vasculogenesis. Fadini et al. also reported that EPCs originate 
in the bone marrow where they are localized in either a quiescent state or a more 
undifferentiated one.  
EPCs can be mobilized from the bone marrow into the peripheral circulation 
in response to many stimuli, including growth factors and cytokines, released by 
ischaemic or damaged tissues, as well as during physiologic processes118. When EPCs 
reside in the blood circulation, they can home specifically towards sites of ischaemia or 
tissue damage, because of the interaction between soluble chemokines and their 
receptors expressed on EPCs surface119-124. Once the EPCs have adhered to activated 
endothelium, they either serve as  patches to repair any endothelial denudation or 
migrate into the surrounding tissue following chemokine gradients. When EPCs are 
exposed to appropriate environmental stimuli, including growth factors and nutrients, 
tissue EPCs proliferate and organize themselves into three-dimensional tubular 
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structures that eventually connect with the pre-existing circulation system and mature to 
become new blood vessels. EPCs consequently show two main activities in the vascular 
system: the healing of endothelial damage and the formation of new blood vessels in 
ischaemic tissues. 
Studies with induced experimental mechanical endothelial damage have 
shown that EPCs are able to repair the vessel wall, re-establishing anatomical and 
functional endothelial integrity125. The functions of EPCs also include paracrine activity 
by the secretion of growth factors and cytokines126 and possible trans-differentiation 
into cardiomyocytes127. 
As a result, EPCs can be considered as an integrated component of the 
cardiovascular system prone to pathological alterations and pharmacological 
modulation. The inability of EPCs to maintain a normal endothelial homoeostasis and to 
promote the development of new vessels appears to be the reason for accelerated 
vascular disease and ageing, with the potential blockage of compensatory angiogenesis, 
thus favouring the development and progression of ischaemic syndromes. Moreover, 
EPC alterations have been shown in subjects with no theorical classic cardiovascular 
risk factors, such as diabetes, hypertension, dyslipidemia, cigarette smoking, obesity 
and a family history of cardiovascular disease128. 
In addition to being altered in the presence of risk factors, EPCs are further 
impaired in patients with early or advanced atherosclerosis. By using different methods, 
it has also been demonstrated that levels of EPCs are directly linked with brachial artery 
flow-mediated dilation, a measure of peripheral endothelial function, regardless of 
classic risk factors.  
A relevant decrease in the level of EPCs represents an advanced 
atherosclerosis of coronary or peripheral arteries129. This evidence indicates that a drop 
in EPCs is in accordance with the natural history of atherosclerosis130. At present there 
is a general agreement concerning EPC levels which provide a measure of the 
endogenous vascular repair capacity related to atherosclerotic burden and influence of 
cardiovascular risk118. 
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1.6.1 Origin of Endothelial Progenitor Cells 
 
Besides the much research interest in the field of endothelial cells, EPCs can 
be isolated by multiple precursors and there has been a great variability in their 
functional evaluation, regarding future characteristics of the cells131.  
Literature has reported several methods for isolating EPCs, and the main 
sources presented are peripheral blood, bone-marrow and umbilical cord blood. 
Ingram et al. found a method based on the clonogenic and proliferative 
potential of EPCs isolated from umbilical cord and adult peripheral blood which was 
strictly related to the hematopoietic cell system, because of its similar clonogenic and 
growth characteristics. In human cord blood the authors identified a unique population 
of high proliferative potential–endothelial colony-forming cells (HPP-ECFCs) that 
could give rise to a substantial number of cells with final secondary and tertiary 
colonies132.  
Kirton instead showed that the isolation of mononuclear cells from 
peripheral blood or bone marrow (seeded on a fibronectin-coated plate in a medium 
supplemented with endothelial growth factors) resulted in an adherent spindle-shaped 
cell expressing endothelial cell (EC) markers and typical endocytosis of acetylated low 
density lipoprotein (LDL). This type of EC could not form EC tube-like structures in an 
in vitro angiogenesis assay model and, most of all, these cells showed leucocytic 
(CD45) and monocytic/macrophages (CD14) markers131. This method which was used 
to isolate mononuclear cells from peripheral blood resulted in a high contamination of 
platelets, also due to their expression of CD31 and vWF133. The further elimination of 
platelets microparticles led to a depletion in the angiogenic properties of the EPC 
medium, thus reporting an in vitro characteristic due to the presence of platelets after 
the mononuclear isolation134. 
Moreover, a similar method to Asahara’s first one consisted in isolating 
CD34+ and VEGFR2+ mononuclear cells from peripheral blood and in cell labelling 
with antigen specific antibodies by employing fluorescence activated cell sorting to 
select EPCs135. After the characterization of putative EPCs by CD34+ marker, Peichev 
et al. introduced a further expression of CD133 in combination with CD34 and 
VEGFR2, showing that the expression of both markers established a phenotipically and 
functionally distinct population of circulating endothelial cells with a role in the 
neoangiogenesis. Under specific stimuli such as incubation with growth factors VEGF, 
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FGF-2 and IGF, the circulating endothelial cells differentiated into mature adherent 
endothelial cells135. Peichev’s findings were later reversed by studies which highlighted 
that those types of cells were not EPCs but distinct primitive haematopoietic progenitors 
also expressing CD45 marker with no ability to form vessels136.    
A method developed by Hill showed the colony forming cell assay to isolate 
EPCs from peripheral blood; this method was further divided into two other assays. One 
derived from a phenotypical expression of EC markers as well as from  haematopoietic 
cell-specific surface antigens (CD14, CD45, CD115) known as Colony Forming Unit 
cells. These cells showed phagocytic abilities, low proliferative activity and were unable 
to form vessels in vivo. Central clustered cells possess myeloid progenitor potential137.  
The other method, involving cells named Endothelial Colony Forming Cells 
which showed robust proliferative potential, highlighted the formed capillary-like 
structures in vitro132 and vessels in vivo with no expression of CD14, CD45 and CD115 
or showed phagocytic abilities. However, previous transplant studies identified a type of 
cell with a similar phenotype residing within the bone marrow138. 
‘EPCs’ appeared to represent two distinct populations with overlapping 
antigen expression (e.g. CD34/VEGFR2).  
 
 
Figure 4. Early- and late-EPCs. Different morphology, proliferative ability, markers expression and in 
vivo properties characterize two different types of EPCs (Kirton J.P., Microvascular Research, 2010).  
 
 
Two different EPC subpopulations, early and late EPC, were described with 
distinct cell growth patterns and the ability to secrete angiogenic factors139, (figure 4). 
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Hematopoietic-derived spindle shaped cells, as described in the first and second method 
(also referred to as circulating angiogenic cells), and CFU colonies were generally 
classified as early-EPCs; they developed after 4-7 days with a peak growth in culture at 
2–3 weeks and died after approximately 4 weeks in vitro. Moreover, they secreted an 
array of angiogenic, antiangiogenic and neuroregulatory cytokines139.  
The Endothelial Colony Forming Cells, the cobblestone shaped cells known 
as late-EPCs, grew after 3-4 weeks with characteristics of mature endothelial cells; they 
represented the limited subset of cells that do not express hematopoietic antigens 
(CD45−)140 and were the only cell type described that exhibited vessel forming ability, 
hence they were considered to be ‘true EPCs’131.  
In consideration of the literature data it can be argued that there is no general 
agreement on the best antigenic combination to define a population of purified EPCs. 
Therefore, it has been suggested to consider the original antigenic phenotype of EPCs as 
those cells positive to CD34 and VEGFR2 markers; this could be the best compromise 
in terms of specificity and sensitivity in the clinical setting, even though it is not 
completely distinguishable between EPCs, mature endothelial cells and haematopoietic 
progenitor cells118. 
 
1.6.2 Homing of Endothelial Progenitor Cells 
 
On account of the vessel forming abilities of EPCs, it is useful to induce the 
late-EPC within the blood system to promote homing to sites of vascular injury and 
ischemia or for ex vivo expansion prior to implantation. The mechanisms of EPC 
homing are still unclear, even though tissue resident EPCs have been identified141. 
The initial steps in mobilization involve the activation of Matrix 
MetalloProteinase-9, which catalyses the conversion of membrane bound Kit ligand to a 
soluble Kit ligand. The subsequent cKit-positive progenitor cells can then move from 
the osteoblastic to the vascular zone of the bone marrow microenvironment131. Several 
studies confirm that this process is enhanced by high levels of SDF-1 and VEGF and 
appears to be nitric oxide dependent142.  
A relevant number of studies have shown that VEGF, SDF-1, in addition to 
G-CSF, GM-CSF, oestrogen, erythropoietin, statins and physical exercise, enhance the 
mobilization of total/early-EPCs within circulation. 
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In comparison to early-EPCs, the number of late-EPCs within the circulation 
was increased by G-CSF, a CXCR4 (SDF-1 receptor) antagonist and statin treatment132.  
Moreover, the proliferation, migration and ability of tube forming via up-regulation of 
CXCR4 and SDF-1 were shown to be improved by an activation of PAR-1 (main 
thrombin receptor expressed by ECs) in vitro143. 
Similarly, the proliferation of late-EPCs and their ability to form vessels 
decreases following exposure to oxidative stress/ROS generation, hyperglycaemic 
conditions, hypoxia or pro-inflammatory stimulation (TNF-α)144. However, inhibition of 
p38 mitogen-activated protein kinase pathway blocked TNF-α induced senescence.  
Using a mouse model of hind limb ischemia, Chavakis et al. demonstrated 
that β2-integrins are involved in the homing of hematopoietic progenitor cells to sites of 
ischemia and that the pre-activation of β2-integrins is fundamental for the 
neovascularization process120. Integrins are crucial transmembrane molecules that 
mediate cell adhesion, migration and the homing of progenitor cells to sites of ischemia. 
Furthermore, Chavakis reported that there is much evidence to support the following 
mechanism of homing. As well as hematopoietic stem/progenitor cells, EPCs express 
β2-integrins. These molecules can be activated by Mn2+ and can mediate the adhesion of 
EPCs to mature endothelial cells, recombinant human ICAM-1 and the fibrinogen; they 
also mediate the chemokine-induced transendothelial migration of EPCs. Moreover, β2-
integrins are involved in vivo in the homing of progenitor cells to the sites of ischemia, 
and the vascular integration of the integrins significantly contributed to the 
neovascularization capacity of infused bone marrow progenitor cells in the mouse 
model of hind limb ischemia. The preactivation of the β2-integrins on EPCs by 
activating antibodies was shown to significantly increase the in vivo neovascularization 
ability of EPCs, indicating a new therapeutic tool to promote the homing of EPCs. β2-
integrins were found not only expressed on differentiated leukocytes but also on 
hematopoietic stem/progenitor cells145. β2-integrins were also shown to mediate 
adhesion and transmigration of hematopoietic stem/progenitor cells146.  
The role of β2-integrins was also to mediate the adhesive interactions of 
EPCs to mature endothelial cells and to extracellular matrix proteins; integrins are also 
crucial for the chemokine-induced transendothelial migration of EPCs in vitro, while in 
vivo they were reported to improve the neovascularization ability of infused bone 
marrow progenitor cells120.  
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As also reported by Yoon et al., the bone marrow-derived EPCs expressed 
β2-integrins, the ligand of ICAM-1, suggesting that ICAM-1/β2-integrin binding plays a 
role in the homing of EPCs to ischemic muscle tissue. The importance of ICAM-1 was 
observed, as confirmed by using a blocking antibody for ICAM-1, which markedly 
decreased both the adhesion of EPCs to endothelial cells in vitro and the homing of 
EPCs to ischemic limb in vivo. Yoon revealed that in response to ischemia, ICAM-1 
was selectively overexpressed in the ischemic muscle compared with the nonischemic 
muscle, suggesting that ICAM-1 could be the key molecule to induce preferential 
recruitment of EPCs to ischemic sites147. 
Carmona later investigated the role of activation of Epac1 (a nucleotide 
exchange protein for Rap1, which is directly activated by cAMP) on integrin-dependent 
homing functions of progenitor cells in vitro and in vivo as a mechanism directing the 
homing of EPCs. Epac1 is expressed in human EPCs and its stimulation with a specific 
pharmacologic activator is able to increase the activity of integrin and integrin-
dependent homing functions, such as adhesion and migration. Moreover, short-term 
preincubation of human EPCs with the pharmacologic Epac activator increased in vivo 
homing to sites of ischemia and neovascularization-promoting capacity of EPC 
suggesting that activation of Epac1 is a useful strategy for increasing the therapeutical 
potential of human EPCs148. 
Another mechanism involved in the homing of EPCs was further assessed by 
Lev and colleagues who found that activated platelets, interacting with EPCs in vitro 
under static and flow conditions, played an important role in the recruitment of EPCs to 
sites of injury149. As previously reported150, activated platelets may facilitate the homing 
of EPCs by recruiting and “directing” them to sites of vascular injury.  
Hematopoietic progenitor cell rolling in murine bone marrow micro-vessels 
is mediated by P- (and E-) selectin and could be inhibited by antibodies to these 
selectins151. The involvement of P-selectin in the platelet-EPC interaction also accounts 
for the need for platelet activation to facilitate this interaction, since platelet P-selectin is 
expressed mainly when platelets are activated152. 
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1.6.3 EPCs and diabetes: impaired function of EPCs and mechanisms involved  
 
Fadini and his colleagues reported that diabetes mellitus is associated with a 
twofold to fourfold increase in the incidence of cardiovascular disease118. The high risk 
of vascular disease in diabetes is generally attributed to the negative effects of 
glucotoxicity and lipotoxicity on the vessel wall in general, and in particular to 
endothelial cells. Endothelial dysfunction and damage is an early and widespread 
complication in patients with diabetes and it is also the first stage in the pathogenesis of 
atherosclerosis153. This could represent, at least in part, the accelerated atherosclerotic 
process that characterizes diabetes mellitus.  
It has recently been discovered that the endothelial repair process plays an 
important role in determining overall vascular health. An impaired endothelium is 
repaired by being partially covered by resident endothelial cells together with the 
contribution of circulating EPCs.  
The reduction of the proliferation rate in culture of EPCs and dysfunction 
has been shown in type 1 and type 2 diabetes; Tepper found that early EPCs from 
patients with type 2 diabetes exhibit impaired proliferation, adhesion and incorporation 
into vascular structures154. 
Loomans et al. obtained similar results in patients with type 1 diabetes, by 
showing a reduced number of early cultured EPCs compared with control subjects. 
Patients’ EPCs were functionally impaired in an in vitro angiogenesis assay and 
conditioned media from patients’ EPCs showed a reduced capacity to support 
endothelial tube formation155. They both showed that the rate of proliferation of EPCs 
from plated PBMCs in diabetic patients was inversely correlated with levels of glycated 
haemoglobin, suggesting a possible relation between glucose control and EPC function. 
Reduced adhesion of EPCs to HUVECs demonstrated altered cell-to-cell interactions 
which could indicate that EPCs are recruited less avidly in vivo at sites of ischemia, and 
also that reendothelization by means of bone-marrow derived cells is less likely to take 
place in the presence of EPC dysfunction. 
Furthermore, compared to matched controls, type 2 diabetes is associated 
with a reduction in circulating CD34+KDR+ EPCs by using a flow cytometry that is not 
subjected to bias inherent in cell culture protocols. Besides CD34+KDR+ cells, generic 
CD34+ cells were also severely decreased in patients with diabetes as compared to 
controls156. It has been found that a smaller but significant reduction of circulating 
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CD34+ cells is detectable in patients with prediabetic conditions, such as impaired 
fasting glucose and impaired glucose tolerance, suggesting that this parameter is an 
early indicator in the natural course of the disease.  
Despite data on in vitro cultured EPCs, the literature does not provide clear 
evidence that apoptosis of EPCs is increased in vivo in patients with diabetes. On the 
contrary, the evidence from in vivo animal experiments has shown that diabetes leads to 
an inability to mobilize EPCs from the bone marrow to the peripheral circulation in 
response to ischaemia. In rats with experimental diabetes, Fadini et al. showed that 
ischaemia reperfusion injury did not trigger any increase in Sca-1+c-kit+ cells (rat 
homologues of EPCs) because of the inability to upregulate the hypoxia-sensing system 
HIF-1α and the defective release of mobilizing cytokines, such as VEGF and SDF-1α. 
As a consequence, post ischaemic angiogenesis was significantly compromised in 
diabetic animals compared to non-diabetic ones157. 
Diabetes represents a clinical condition connected to an extensive progenitor 
cell reduction158. Hypothetical mechanisms that could account for circulating EPC 
reduction in diabetes include: (i) decreased survival; (ii) altered mobilization from the 
bone marrow; (iii) deranged differentiation and (iv) extravascular homing or waste. 
Regarding the mechanisms involved in the impaired function of EPCs within 
diabetes, besides several factors that have been involved in EPC mobilization, 
proliferation, migration, their differentiation and homing to sites of vascular injury, it 
was found that the expression of angiogenic factors, such as VEGF and hypoxia-
inducible factor-1 (HIF-1) is reduced in the hearts of diabetic patients during acute 
coronary syndromes159. The expression of HIF-1 gene decreases in hyperglycaemic 
conditions and is associated with myocardial infarct size in rats160.  
SDF-1, also known as CXCL12, and its receptor CXCR4 played a critical 
role in regulating hematopoietic cell trafficking. In non-obese diabetic mice, the onset of 
diabetes is significantly delayed by reducing the level of SDF-1, either by antibody-
mediated neutralization or G-CSF-induced suppression of SDF-1 transcription161. In a 
diabetic environment, EPCs could decrease because of increased apoptosis, as 
confirmed by many studies. 
In rats with streptozotocin-induced diabetes, reduced circulating EPC levels 
were associated with uncoupled eNOS in bone marrow162. Dernbach showed that EPCs 
are more protected against oxidative stress compared to mature ECs, and therefore it 
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seems unlikely that the decrease and dysfunction of EPCs are mediated by an increase 
in oxidative stress163.  
Furthermore, a dysfunction of EPCs in type 2 diabetes patients was 
associated with oxidative stress due to a significant production of reactive oxygen 
species (ROS). A prolonged exposure of EPCs to high glucose concentrations in vitro 
increased superoxide anion production, and reduced NO bioavailability164. A generation 
of superoxide anions appeared by using several processes that included glucose auto-
oxidation, increased protein kinase C (PKC) and NAD(P)H oxidase activity165.  
 
1.6.4 Mobilization of EPCs into the circulation 
 
As previously reported, EPCs can be released into the circulation in response 
to injury (e.g. ischaemia) or mobilizing or angiogenic factors, though without the 
presence of specific biomarkers, the identity of the mobilized cells and the site of 
mobilization are still unclear. 
Several studies have been carried out with regard to burn injuries and it is 
widely accepted that VEGF is one of the most largely studied angiogenic factors. Gill et 
al. demonstrated that VEGF levels were high in the plasma of patients 6–12 h after burn 
injuries or coronary artery bypass grafting, and this further correlated with the rapid 
mobilization of proangiogenic cells into the bloodstream, with a return to basal levels 
by 48–72 h post-injury166. 
Levels of factors such as VEGF and SDF-1 in adult human peripheral blood 
were linked to the severity or total surface area of the burn injury;  these factors reached 
their maximum within 24 h of the thermal injury and declined over several days to 
weeks167. 
ECSM2, known as endothelial cell-specific chemotaxis receptor (ECSCR), 
is an endothelial-restricted cell surface receptor that appears to enhance the sensitivity 
of VEGF in angioblasts during vasculogenesis. This receptor was found to be increased 
in the plasma of burn patients168. The increased levels of  ECSM2 continued to remain 
high even after VEGF was shown to decrease169. 
These data suggested that after a burn injury and increased levels of 
circulating VEGF and SDF-1, both proangiogenic and endothelial cells were rapidly 
mobilized into the peripheral blood. Pro-inflammatory factors, such as eotaxin and 
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granulocyte colony-stimulating factor (G-CSF), have also been shown to be elevated 
after burn injury170. 
Several studies were recently reported concerning  mobilizing factors and 
heart disease. Hill and his colleagues indeed reported that patients at risk of developing 
cardiovascular diseases have a reduced number of proangiogenic cells in their 
circulation137, while others found conflicting data on the number of such cells in 
patients with coronary artery disease171. As for severe burn injuries, acute myocardial 
infarction (AMI) can produce a rapid mobilization of proangiogenic cells into the 
circulation; this effect is related to increased levels of circulating angiogenic factors.  
In a study aimed at examining the role of EPCs and their precursors CD34+ 
mononuclear cells in the mobilization in patients with AMI, enhanced VEGF levels in 
the circulation of patients 3–28 days post-AMI was observed. These data was related to 
high levels of cells, identified by phenotypically proangiogenic cells172.  
Another study showed relevantly increased numbers of circulating cells with 
a proangiogenic phenotype in the early stage after AMI. These cells reached maximum 
growth within 7 days post-AMI and then declined to basal levels after 60 days. The 
increased levels of ‘proangiogenic progenitor cell’ strongly correlated with increased 
VEGF levels in the patients’ plasma173. In the circulation of patients affected by AMI 
increases in VEGF, G-CSF and CXCL12 levels171 have been reported, even though it 
has been shown that VEGF presents two patterns of release during AMI: the first in the 
acute phase (24–48 h) and the second in the subacute phase (7 days)174.  
Leone later suggested that an increase in CD34+ cell mobilization and the 
conflicting coronary artery disease data on cell mobilization can be correlated with the 
myocardial ischaemic burden in these patients171. At the same time, it has been 
demonstrated that for those patients affected by AMI, the proangiogenic cells were 
mobilized due to acute cardiovascular injury173. 
 
1.6.5 EPCs in the clinical practice 
 
A relevant number of early studies in animal models showed that the bone 
marrow or blood-derived EPCs could improve vascular repair. Research using animals 
was carried out on several vascular pathologies such as hindlimb ischemia, acute 
myocardial infarction, and cardiovascular diseases linked to diabetes. As a result, in the 
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last ten years emerging studies on the proangiogenic role of EPCs in wound repair and 
tissue regeneration were translated into early clinical trials.     
Several efforts focused on treating cardiovascular disease by means of 
mononuclear cells or CD34+/CD133+ cells selected from mobilized peripheral blood, 
bone marrow or cultured MSCs170.   
Other studies were developed on animal models of hindlimb ischemia as 
reported by a substantial amount of data in literature and briefly exposed as follows. 
Kalka175 performed a transplantation with human endothelial progenitor cells 
(hEPCs) in an athymic nude mice model of hind limb ischemia. hEPCs were isolated 
from human peripheral blood and after ex vivo expansion were systemically injected to 
assess the enhancement of neovascularization in ischemic tissues. It was observed that 
not only did the heterologous cell transplantation improve neovascularization and blood 
flow recovery, but the improved perfusion was sufficient to increase the success of limb 
salvage (reduction of the rate of limb necrosis and autoamputation). 
Chavakis120 subsequently used murine Sca-1+/Lin- hematopoietic progenitor 
cells from β2-integrin–deficient mice in an attempt to demonstrate the role involved by 
integrins in the adhesive interaction of progenitor cells to mature endothelial cells. The 
group studied a mouse model of hind limb ischemia by intravenous infusion of bone 
marrow hematopoietic progenitor cells: the result was an incorporation of the 
transplanted cells in newly formed vessels and an improvement of neovascularization.  
With the aim of confirming in vitro data showing that E-selectin was expressed on 
activated endothelial cells, Nishiwaki performed a transplantation of EPCs in a murine 
ischemic hind limb model. The group used HUVECs transduced with a recombinant 
adenovirus of E-selectin (AdRSVE-sel) or that of β-galactosidase (AdRSVLacZ) and 
their effect was examined in the ischemic model. A significant improvement of tissue 
recovery with an enhancement in neovascularization was observed in mice 
overexpressing E-selectin following EPC transplantation. 
In the same model of hindlimb murine ischemia, it was thought that a local 
injection of sE-selectin to an ischemic limb could enhance the recruitment of 
transplanted GFP-positive EPCs from the systemic circulation to an ischemic limb in 
WT mice. The incorporation of transplanted EPCs into the microvasculature of 
ischemic limbs was further quantified. The histological examination showed that sE-
selectin pretreatment increased EPC homing in the ischemic muscle just seven days 
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after the systemic injection, thus the number of EPCs able to home to ischemic limbs 
was markedly increased by sE-selectin176. 
Besides limb ischemia, progenitor cells were also employed as cell therapy 
in some pathologies in animal models as well as in human trials.  
Functional alterations similar to those observed in diabetic patients were found in EPCs 
isolated from aged patients with coronary artery disease or ischemic cardiomyopathy177. 
The number of EPCs has been greatly associated with a risk of 
cardiovascular disease, as suggested by the result that EPCs circulating expression level 
predicted the occurrence of cardiovascular events and vascular tissue injury178. 
In a swine chronic myocardial ischemia model a catheter-based 
transplantation of a freshly isolated, autologous EPC-enriched fraction was performed. 
In order to verify the therapeutic usefulness of these cells, they were transplanted into 
the myocardium in a nude rat model of myocardial ischemia. As a result, the locally 
transplanted CD34+ cells were integrated into the foci of myocardial neovascularization 
and differentiated into mature ECs, consequently they enhanced vascularity in the 
ischemic myocardium thus preserving left ventricular systolic function. The 
reendothelialization of the denuded blood vessels, neovascularization and paracrine 
effect were considered to be the mechanisms involved in EPC-mediated myocardial 
protection and repair after acute myocardium ischemia. 
In a pilot study of cell therapy for ischaemic cardiomyopathy, progenitor 
cells cultured from patients’ peripheral blood were compared with freshly isolated bone 
marrow mononuclear cells. The aim was to assess if an intracoronary infusion of 
progenitor cells into the infarct-related artery at least 3 months after myocardial 
infarction could improve global and regional left ventricular function. The results 
demonstrated that infusion of progenitor cells derived from bone marrow into the 
infarct-related artery was associated with moderate but significant improvements in both 
global and regional left ventricular contractile function, showing that only bone marrow 
and not peripheral blood progenitor cells were able to improve left ventricular ejection 
fraction179. 
Due to promising results from clinical trials of cell transplantation involving 
endothelial progenitor cells (EPCs) in hindlimb and cardiac ischemia models, other 
settings of occlusive thromboatherosclerotic diseases, such as strokes, were considered 
where the acceleration of angiogenesis might be expected to enhance the outcome. It 
was demonstrated that in immunocompromised mice subjected to stroke, 48 hours 
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earlier a systemic administration of human CD34+ cells led to an acceleration in the 
neovascularization at the border of the ischemic zone followed by endogenous 
neurogenesis180. 
Recently ex vivo expanded EPCs were injected via the jugular vein after 1 
hour of transient middle cerebral artery occlusion (tMCAO) in a mouse model in order 
to explore the role of EPCs following ischemic brain injury. After 3 days of MCAO, 
EPC transplantation prominently decreased the ischemic infarct volume compared to the 
control. EPC therapy reduced mouse cortex atrophy 4 weeks after tMCAO, and was 
accompanied by improved neurobehavioral outcomes; moreover, the injection of EPCs 
was able to strongly increase angiogenesis in the periinfarction area. Following  a long-
term stroke, the systemic delivery of EPCs was shown to be protective against cerebral 
ischemic injury thus promoting neurovascular repair181. 
The possibility of cellular therapy with EPCs as a treatment of diabetic 
macular ischemia and the vasodegenerative phase of diabetic retinopathy was discussed 
by Li Calzi182. Diabetic retinopathy is thought to largely be a result of diabetes-induced 
retinal microvascular dysfunction and is characterized by capillary leakage (loss of the 
functional integrity of the blood retinal barrier) or capillary closure resulting in ischemia 
(the formation of acellular capillaries, with loss of blood supply to the neural retina). 
The same group observed that relevant numbers of bone-marrow derived cells 
contributed to both repair and improve pathological neovascularization in the eye.  
It was investigated whether EPCs isolated from healthy patients were  better 
able to repopulate degenerate (acellular) retinal capillaries in chronic (diabetes) and 
acute (ischemia/reperfusion [I/R] injury and neonatal oxygen-induced retinopathy 
[OIR]) animal models of ocular vascular damage. The results were that healthy human 
CD34+ cells could repair injured retina and there was a defective repair of vasculature 
in patients with diabetes183. 
In order to observe the role of hematopoietic stem cells in revascularizing 
ischemic retinas a novel model of retinal neovascularization in adult mice was 
developed. Progenitor cells were durably engrafted and afterwards retinal ischemia was 
induced to promote neovascularization184. 
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1.7 Mesenchymal Stem Cells 
 
Stem cells possess two properties: 
- self-renewal: the ability to go through numerous cycles of cell division while 
still maintaining their undifferentiated state; 
- potency: the ability to differentiate into specialized cell types under appropriate 
stimuli, (figure 5). During the regeneration process a stem cell, just like at the  
beginning of the process, and the second is a progenitor cell that gives rise to a 
specialized cell under the right stimuli. The stem cells are divided into three 
classes: 
- totipotent; 
- pluripotent; 
- multipotent; 
- oligopotent; 
- unipotent. 
The zygote, the only totipotent cell (the first few divisions of the fertilized 
egg), has the potential to create all cells and tissues that generate the embryo and 
support its development in the uterus. This stem cell can differentiate into embryonic 
and extraembryonic (umbilical cord and placenta) cell types and create a complete, 
viable organism185.  
Pluripotent stem cells come from totipotent cells and can differentiate into 
nearly all cells, mainly the three embryonic sheets: mesoderm, endoderm and ectoderm. 
These sheets create all body cells, thus pluripotent cells are able to give rise to all cell 
types. Embryonic stem cell lines (ES cell lines) come from the inner cell mass of the 
blastocyst, one of the early stages of embryonic development, prior to the embryonic 
implantation in the wall of the uterus. ES cells are pluripotent because during their 
development they give rise to all derivatives of the three primary germ layers: ectoderm, 
endoderm and mesoderm186. 
Multipotent stem cells can differentiate into a number of cells, but only those 
of a closely related family of cells. 
Oligopotent stem cells can differentiate into only a few cells, such as 
lymphoid or myeloid stem cells. 
Finally unipotent cells can produce only one cell type (their own) but have 
the property of self-renewal and differentiate into all cell types of the tissue from which 
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they are created, and they are also distinguishable from non-stem cells (adult stem cells, 
undifferentiated, not specialized).  
 
 
Figure 5. Potency of cells. The pluripotent stem cells, deriving from the inner mass of the blastocyst, give 
the three embryonic sheets that further develop their stemness into any tissue in the body except a 
placenta. The morula is the only cell able to develop in all tissues and a placenta (totipotency).  
 
Adult stem cells, typically present in healthy tissues, give only one cell line 
in normal conditions and this mechanism guarantees the renewal of the tissue. 
Nevertheless, if the tissue is impaired, it is necessary to recreate more cell types, so 
pluripotent stem cells are activated187.  
Most adult stem cells are generally referred to by their tissue origin (bone-
marrow, cornea, retina, dental pulp, fat, liver, skin, endothelium, etc)188. Among the 
various stem cells, a relevant role is given to mesenchymal ones, which are able to 
create all the cells of the mesodermic line. 
In 1924 Alexander A. Maximow, Russian morphologist, used extensive 
histological findings to identify a singular type of precursor cell within mesenchyme 
that developed into different types of blood cells189. Later, scientists Ernest A. 
McCulloch and James E. Till first revealed the clonal nature of marrow cells in the 
1960s190.  
An ex vivo assay for examining the clonogenic potential of multipotent 
marrow cells was reported only in the 1970s by Friedenstein and colleagues: stromal 
cells, which referred to an adherent cell population and had an elongated shape were 
similar to fibroblasts called colony-forming unit-fibroblasts (CFU-F). These cells were 
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able to differentiate into osteocytes, thus they were also identified as osteogenic 
precursors191. Further studies showed their differentiative potential which has also been 
used in the mesodermic line, with relation to condrocytes, tenocytes and myoblasts192. 
Based on these several differentiation abilities, in the 1980s Caplan 
introduced the expression Mesenchymal Stem Cells, MSCs193. Though MSCs are 
subjected to adult stem cells criteria, such as self-renewal and differentiative potential, 
the problem of whether the term “stem cell” is appropriate when referring to a single 
MSC cell remains unsolved. It was proposed recently to use a new expression 
“multipotent mesenchymal stromal cells”, maintaining the acronym MSCs, to describe 
fibroblast-like plastic-adherent cells194. 
Later Bonnet and colleagues were able to isolate a single-cell-derived 
population capable of differentiating abundantly into different mesenchymal cell types 
in vivo from the murine mesenchymal compartment; they identified a subpopulation 
based on the expression of stage-specific embryonic antigen-1 (SSEA-1)195. 
MSCs were initially isolated by bone marrow196 and were subsequently also 
cultured from adipose tissue, placenta, amniotic fluid and fetal tissue such as lung and 
blood, as well as from Umbilical Cord Blood (UCB). In each tissue originating from the 
mesenchyme, MSCs can maintain a physiological cell turn-over even if present only in 
a minimal amount197.  
There is still controversy today surrounding the phenotypic definition of 
MSCs. In fact there is no marker or combination of markers that could define MSCs in a 
unique way, so a different series of factors that need to be verified are considered194. 
Expanded MSCs express the following markers: CD105 (SH2 or endoglin), CD73 (SH3 
or SH4), CD90, CD166, CD44 and CD29196. Hematopoietic or endothelial markers are 
not expressed by MSCs: CD11b, CD14, CD31 and CD45196. 
At present, the functional standard used to define MSCs is based on their 
differentiative ability in several mesenchymal lines, such as osteocytes, adipocytes and 
condrocytes. Pluripotent cells were recently shown to differentiate not only in the 
mesoderm line, but also in the endoderm and the neuroectoderm line, as neurons, 
hepatocytes, and endothelial cells. These cells were identified in bone marrow and were 
named as multipotent adult progenitor cells (MAPC)198, hBMSCs (“human BM-derived 
multipotent stem cells”)199, MIAMIs (marrow isolated adult multilineage inducible 
cells”)200 and VSELs (very small embryonic-like stem cells)201.  
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Similar pluripotent cells were also found in adipose tissue202 and more 
recently in amniotic fluid. Particular growth conditions are required to culture these 
primordial cells, such as fibronectin-coated culture dishes, a culture medium rich in 
growth factors and a long culture time with low cell density. Compared to these, a 
higher density culture can stimulate the differentiation towards mesenchymal 
progenitors with reduced differentiative potential.  
It has not been possible until now to isolate such cells from fresh tissues, 
blood or bone marrow; at present it is not still clear whether these are primary cells with 
a physiological role or whether they are the result of a prolonged culture in specific 
conditions. 
Due to the lack of specific markers, the isolation of MSCs is based on their 
plastic adherence, obtained from a heterogeneous population of adherent cells. MSCs 
are structural components of the bone marrow stroma, which support the hematopoiesis 
by producing extracellular matrix components, like cytokines and growth factors. The 
main physiological role of MSCs is their ability to repair cells, which are ready to 
mobilize and differentiate in response to signals of pathological or traumatic 
conditions203. 
 
 
Figure 6. Mesenchymal Stem Cells in the bone-marrow niche 
 
Even though bone marrow is the main source, the extraction site of MSCs 
influences the behaviour of isolated cells; those extracted from alveolar bones show less 
condrogenic and adipogenic potential than those isolated from iliac bones.  
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MSCs are a small cell component, but generally using 10-20 ml of bone 
marrow aspirate it can be isolated and expanded to form hundreds of colony-forming 
cells. The isolation begins through centrifugation with a different density gradient to 
separate the bone marrow mononucleated fraction as well as to exploit the adherence 
ability of MSCs to culture over plastic dishes204. The colony-forming unit test (CFU) is 
an in vitro method used to evaluate proliferative capacity and count colonies derived 
from single cell expansion. These populations are expanded for 40-50 cycles until they 
reach  the "Hayflick limit"; they do not lose  their multipotential characteristic although 
their proliferative characteristic is prone to decline. 
Immunological studies evaluated MSCs as surface markers involved in T 
lymphocytes interaction such as the adhesion molecules VCAM-1, ICAM-1196; they 
also express the HLA205, the MHC-I and also negligible levels of MHC-II and Fas 
ligand, but they do not express B7-1, B7-2 and CD40. Besides the MSC characteristic 
found in the bone marrow, these markers indicate their role in the immunoregulation 
processes. 
MSCs were found to alter cytokines secretion by means of dendritic cells 
(DCs), T naïve and effector cells (Th1, Th2) and natural killer cells (NK), inducing an 
anti-inflammatory and more tolerant phenotype206, (figure 7). 
 
 
 
Figure 7. Proposed mechanisms of action of MSCs. The immunomodulatory effect of MSCs due to 
interactions with both the innate (DC, pathways 2-4; NK cell, pathway 6) and adaptive immunity systems 
(T cell, pathways 1 and 5). The DC maturation state could be influenced by MSC inhibition of TNF-α 
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secretion and promotion of IL-10 secretion with a resultant switch of the immune response toward in an 
anti-inflammatory/tolerant phenotype. MSCs could also inhibit IFN-γ secretion from Th1 and NK cells 
and increase IL-4 secretion from Th2 cells, thus reporting a Th1 -> Th2 shift (Aggarwal S., Blood, 2005). 
 
Interaction between allogeneic MSCs and immune system cells can play a 
basic role in vivo in the induction of tolerance; indeed, MSCs mediate the reduction of 
the incidence and the severity of GVHD62, as well as prolong graft survival in skin 
transplantation, reduce inflammation and suppress lymphocytic responses in allogeneic 
transplants207. 
In allogeneic settings these properties of MSCs were exploited as a valid 
alternative to immunosuppressive treatment due to the avoidance of side effects linked 
to the actual use of immunosuppressive pharmacological protocols208.  
At present, one of the unsolved questions on the use of mesenchymal stem 
cells in grafts is their dispersion in the entire body of the recipient. Several studies 
showed the ability of autologous and allogeneic MSCs to migrate and establish 
themselves in different tissues and organs of the recipient: gastrointestinal tract tissues, 
kidneys, skin, thymus, liver, spleen, bone marrow and mesenchymal tissues, even 
though data report that the preferred destination of MSCs after the transplant is the 
lung209. 
Mesenchymal stem cells are probably trapped into the lungs because of the 
major difference between the cell diameter and the inner diameter of the capillary lung 
lumen (> 15μm vs. 10 μm, respectively)209. 
Allers showed that the lung of a murine recipient is the long term destination 
site of human MSC. A similar distribution of MSCs was observed both for cells injected 
into the venous circle or the arterious one210; the distribution is time dependent211 and, 
in a non-conditioned recipient, the level of grafted cells after a transplant is relatively 
low210. 
 
1.7.1 Mesenchymal Stem Cells and islets 
 
In 2008 Jacobson studied the role of MSCs in the rejection of allogeneic 
pancreatic islet transplantation in a BALB/c mouse strain model in order to evaluate the 
immunosuppressive properties of MSCs. Since the MSCs showed the capacity to 
suppress T cell proliferation in vitro, Jacobson demonstrated that mice transplanted 
under the left kidney capsule with allogeneic islets and cultured BM-derived stromal 
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cells had a minor grade of rejection compared to mice receiving islets alone, suggesting 
also a prolongation in the survival of transplanted islets212. 
Later Figliuzzi et al., who used the same site of injection, reported that co-
transplantation of MSCs with pancreatic islets improved islet graft function with a 
promotion in graft vascularization. They showed that co-transplantation of 2,000 
pancreatic islets and 1x106 bone marrow–derived MSCs, under the kidney capsule of 
syngeneic diabetic-induced rats, were effective in that the number of capillaries 
increased when compared to animals receiving a greater number of pancreatic islets 
alone. MSCs were also able to reduce the number of transplanted islets by 30%.213  
Moreover, Xu explored the ability of MSCs on blood glucose levels when 
administered by intraperitoneal injection in diabetic-induced rats if MSCs were cultured 
with rat pancreatic extract (RPE). MSCs treated with RPE were found to secrete several 
growth factors such as IGF-1, VEGF, bFGF which were considered as trophic factors 
when compared to the cytokines produced by normal RPE or either MSCs alone 
treatment. Secreted factors by conditioned RPE-treated MSC media showed to be 
preventive against apoptosis in pancreatic beta cells as supported by histological 
evaluation and morphometric evidence; what is more, a significant decrease in blood 
glucose levels was found214. 
Similarly, MSCs enhanced the survival of insulin-secreting β-cells when 
MSCs were injected together with islets into the omental pouch. By transplanting a 
mean value of both syngeneic 700 IE and 3x106 MSCs in a diabetic STZ-induced rat 
model there was an enhancement in long-term islet graft survival. The same protocol 
using allogeneic cells did not exhibit a similar long-term efficacy, thus demonstrating 
that the long-term survival was dependent on the presence of autologous MSCs215.  
Park et al. hypothesized that MSC-secreted molecules would induce a 
trophic effect in pancreatic islet culture conditions. They showed an improvement in 
islet survival and function after islet transplantation and human MSC-conditioned 
medium in a mouse streptozotocin diabetes-induced model216. To this aim, since 
successful islet transplantation is dependent not only on the number or mass of the 
islets, but also on the stable engraftment and prevention of immune-mediated rejection 
of transplanted islets, Park was intended to demonstrate the involvement of trophic 
agents in improving islet survival. In this context MSCs are known to repair and 
regenerate tissue through the secretion of active or trophic factors217.  
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Therefore the role of appropriate trophic molecules that could effectively 
inhibit islet quality degradation during islet culture was investigated as well as whether 
MSCs might secrete active agents able to maintain islet viability and function. By using 
islet-MSC co-culture and islet culture using MSC-conditioned medium, in vitro data 
reported an improvement in insulin secretory function and viability for islets. 
Differences in VEGF and angiogenesis-related signalling as well as β-cell function 
enhancement supported the hypothesis that increased blood vessel formation of MSC-
CM–cultured islet grafts is caused by a trophic factor related to MSCs, which induces 
signals involved in β-cell survival and intra-islet endothelial revascularization. Islet 
transplantation performed under the kidney capsule together with human umbilical cord 
blood-derived MSCs reported an increase in the intensity of insulin staining and 
significantly enhanced blood vessel formation in islets cultured with MSC-conditioned 
medium, as well as a facilitated regulation of blood glucose at normoglycaemic levels 
and body weight gain. 
Finally, trophic agents secreted by MSCs were responsible for the prevention 
of islet cell death due to the induction of anti-apoptotic and survival signalling, the 
improvement of islet function, and the stimulation of migration and revascularization of 
intra-islet endothelial cells. Islets co-cultured with MSCs revealed enhanced islet 
quality, thus demonstrating the in vivo glycemic control. It can be said that MSC-
originated factors have a positive effect on isolated islets216. 
Analogous results about the protective role exerted by MSCs in islet 
transplantation was further assessed by Ito et al. who performed an islet transplantation 
with 500 IE combined with 107 MSCs in the portal vein of diabetic-induced animals. 
The in vivo data reported that the co-transplantation of MSCs promoted capillary 
formation in and around the islets, showing an increased vWF-positive cell per β-cell 
ratio. The increased capillaries per β-cell ratio in vivo supported the MSC-mediated EC 
proliferation; some detected MSCs were found to express VEGF, which contributed to 
new capillary formation. From histological sections it was reported that the islets 
transplanted with MSCs maintained a normal, undisturbed structure, whereas islet-alone 
transplants appeared fragmented. MSCs prevented cell loss during the early post-
transplantation period and the loss of islet cells may also be caused by proinflammatory 
cells and cytokines. Finally, they argued that the co-transplantation of islets and MSCs 
significantly reduces the number of islets required for diabetes reversal by promoting 
graft revascularization and improving islet cell survival and graft function218. 
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In order to evaluate the effect of MSCs with islets and determine their role 
on the remodelling process, the graft function in a mouse model of minimal islet mass 
was recently studied. In the syngeneic mouse model of diabetes the effect of co-
transplanting kidney-derived MSCs on the morphological and vascular engrafting, as 
well as the function of the transplanted islets, was assessed.  
 
1.7.2 Mesenchymal Stem Cells and Endothelial Progenitor Cells 
 
Another intriguing tissue-engineering system was the co-culture between 
MSCs and endothelial cells in several scaffold systems. 
Since MSCs and pericytes have a similar vessel-support role due to their 
migration towards vessels in response to factors secreted by EC, MSCs can be 
considered as interacting with vascular signals in vivo because of their location in the 
perivascular niche. In 2009 Lozito studied the interaction between MSCs and micro-EC 
found in the microvasculature as capillaries, and macroEC found in the larger blood 
vessels219. These ECs are considered to be in cell-surface markers, and cellular and 
matrix interactions. He focused on the effects of extra cellular matrix produced by ECs 
(EC-matrix) on MSC differentiation. As ECs re-establish the differentiation signals 
which enable MSCs to be involved in the perivascular niche, a possible role for MSCs 
was also investigated in order to  understand an involvement in the vascular milieu 
better. By analyzing the co-culture system EC-MSC, macro-EC were reported to be 
involved in smooth muscle cells interaction. Similarly, micro-EC deriving from 
capillaries without interacting with smooth muscle cells can only support EC-
differentiation. In this context, MSCs cultured on macro-EC matrix were able to 
develop  both ECs and smooth muscle cells differentiation, while their culture on micro-
EC matrix only revealed an EC-differentiation. This study also highlighted an increase 
in MSC expression of vascular cells markers with the development of functional 
vascular cell phenotypes, as MSCs cultured on EC-matrix showed subcellular 
cytoskeletal protein distributions similar to those of vascular smooth muscle cells and 
improved incorporation into EC tubes on Matrigel. 
Finally, EC-matrix supports MSCs differentiation toward EC and smooth 
muscle cells lineages219. 
Aguirre et al. later studied the physical and biochemical interactions between 
BM-EPCs and MSCs in an in vitro co-culture system to explain their roles in 
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vascularization, through BM-EPCs obtained from hematopoietic stem cells expressing 
Flk-1+ CD34+220. If BM-EPCs were mature enough, the co-culture caused angiogenic 
differentiation and tubulogenesis221. The co-cultures of BM-EPCs and MSCs studied by 
Aguirre were examined for 14 days; an early high cell motility was observed with the 
subsequent reorganization and formation of multicellular, elongated structures and the 
stabilization of cell–cell contacts. 
The BM-EPCs/MSCs co-culture demonstrated the importance for direct cell 
contact, as seen by the early formation of stable cell unions, since many cells presented 
dual fluorescence in the first few hours in culture and the number of cells increased over 
time. The functional ability of co-cultured cells to form pre-vascular structures was 
evaluated by co-culturing BM-EPCs/MSCs in Matrigel-coated plates. With no VEGF 
supply, the co-cultured system developed into tube-like structures, even in serum-
starved conditions, highlighting the importance of paracrine signalling, which can be 
attributed to cytokine production.  
Aguirre and colleagues also showed that MSCs participated in tube-like 
formation analogously to BM-EPCs, thus providing evidence that MSC could 
differentiate to endothelial-like cells or vessel supporting cells. Another important result 
was the reduced cell proliferation in the co-culture system in line with the 
differentiation and formation of tight links observed both in Matrigel and normal 
conditions. 
The cross-talk between BM-EPCs and MSCs was also investigated with the 
aid of angiogenic markers to determine the temporal profile in a 14-day period. The first 
three days marked an up-regulation of cell–cell and cell–matrix adhesion proteins, 
growth factors and signalling cytokines (Cdh-5, PECAM-1, Angpt-1, Flt-1, VEGFR-1 
and Matrix metalloproteases), while growth factor members of the TGF-b family, 
VEGF-B, VEGF-C and the transcription factor inhibitors of differentiation Id1 and Id3, 
were down-regulated. In contrast, VEGF-A was slightly down-regulated at all points of 
time. The TGF-b family down-regulation was considered to be the cause of the reduced 
cell proliferation in the co-culture system222. 
A similar system of co-culture was the recently found peripheral blood-
derived Outgrowth Endothelial Cells (OEC)/bone-marrow-derived MSCs in EGM-2, a 
special endothelial medium. The OEC supported the neovascularization process by also 
forming perfused vascular structures after co-implantation with other cell types. The co-
culture system in EGM-2 medium arranged more microvessel-like structures compared 
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to co-cultures in the medium for osteogenic differentiation of MSCs due to an increased 
release of angiogenic factors by the mesenchymal cells in the co-culture and an increase 
of markers and growth factors associated with vessel stabilization by pericytes. 
Although MSC are considered to be a natural source of angiogenic growth factors, the 
cell culture medium also appears to have a significant impact on the angiogenic 
activation of endothelial cells in the co-culture. The increased arrangement of vascular 
structures in EGM-2 is related to higher levels of the proangiogenic factors VEGF and 
PDGF in the supernatant of co-cultures as well as in monocultures of MSCs when 
cultivated in EGM-2223.  
As mentioned above, pericytes play a crucial role in the process of vessel 
stabilization and are essential for building long-lasting vessels after the implantation of 
prevascularized constructs. They are resident in the outer wall of microvessels and have 
stabilizing functions relevant to angiogenesis224.  
Some studies report that pericytes may derive from MSC residing along 
abluminal surfaces of the microvasculature where they interact directly with vascular 
endothelial cells225. Furthermore, pericytes express PDGF-b receptors while MSC and 
endothelial cells release PDGF-BB, thus providing a paracrine interaction between 
pericytes, MSC, and endothelial cells226.  
The increased expression observed of sm-actin and desmin in co-cultures of 
MSC and OEC in response to EGM-2 has to be related to increased PDGF levels in co-
cultures and monocultures of MSC when cultured in EGM-2, indicating an effect of the 
medium on factors responsible for vessel stabilization223. 
 
1.7.3 Mesenchymal Stem Cells – Endothelial Progenitor Cells – Pancreatic Islets 
 
In order to enhance the islet angiogenesis better, MSCs were added to the 
culture medium of EC with isolated islets. The ability of ECs (with or without MSCs) to 
adhere to and grow into human islets was analyzed and when MSCs were present this 
ability was enhanced by covering the islet surface. In a system consisting of MSCs 
cultured with islets, the EC sprout formation was mostly stimulated in the islets where 
intra-islet capillary-like structures were formed. 
The stimulatory effects of MSCs on angiogenesis in three-dimensional fibrin 
gels were reported to induce vessel formation caused by the probable degradation of the 
fibrin matrix by proteases produced by the MSCs, and sprout formation was improved 
 57
in matrices in which the matrix density was too high for the ECs to invade when they 
were cultured alone227.  
Since MSCs were able to drive the EC migration into dense micro-organs 
such as islets, the MSCs provide growth factors and extracellular matrix able to support 
the stabilization and maturation of the EC sprouts228.  
In fibrin gels the MSCs were evidenced by the increased sprout formation by 
EC-MSC islets, where a tight link between EC sprouts and MSCs occurred with a high 
degree of frequency. Compared to untreated islets, in the formation of EC-MSC islets 
and their culture (6 days) no additional loss of islets was observed. To promote EC 
adhesion and proliferation on the islet surface, the microvascular EC survival was 
applied; furthermore, the culture conditions did not promote the pro-inflammatory and 
pro-coagulant capacity of ECs (same expression of TF, IL-6, IL-8 or MCP-1 between 
the EC-MSC and control islets). The authors finally suggested that the use of composite 
EC-MSC islets could have beneficial effects on revascularization and immune 
regulation, constituting a technique for improving islet engraftment229. 
 
1.7.4 Mesenchymal Stem Cells and revascularization 
 
As reported by Wu BM-MSCs were able to promote angiogenesis in a model 
of BM-MSC-treated wounds in diabetic mice230; this supported previous findings 
concerning newly formed granulation tissue and the survival of keratinocytes in the 
formation of new blood vessels during the process of neovascularization231.  
In this model, BM-MSCs were not found in the vascular structures but in 
close proximity, so the paracrine effect of BM-MSCs in angiogenesis was then 
examined; BM-MSC conditioned medium promoted endothelial tube formation and 
expressed high levels of VEGF-α and ANG-1 but not ANG-2, highlighting the 
neovessel structure role230. The results of Wu demonstrated that BM-MSCs engrafted in 
the wound release proangiogenic factors, with a consequent role for MSC mediated 
enhanced angiogenesis230. 
A system consisting of direct interactions between BM-MSCs and vascular 
endothelial cells with no further addition of dermal fibroblasts was shown to be 
involved in the release of angiogenic factors to regulate vessel formation in vitro. In  an 
attempt to use a suitable in vitro model to provide both essential matrix molecules and 
proangiogenic factors, Sorrell et al. investigated whether a Matrigel modified model 
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could provide enough quantities of growth factors to sustain vascular cords through the 
inclusion of BM-MSCs instead of growth factors. The influence of BM-MSC was found 
to release both angiogenic and stabilization factors and adult human BM-MSCs acted as 
facilitator cells with respect to the angiogenic process232. 
Bianco finally found that mesenchymal stem cells were able to contribute to 
the formation of blood vessels  given an adequate supply of differentiated endothelial 
cells. He defined this characteristic as angiopioiesis, to be distinguished from 
angiogenesis and vasculogenesis. The angiopoietic property of ‘‘MSCs’’ is their ability 
to supply ‘‘mural cell’’/pericyte characteristics where angiopoietin-1 (a gene mediating 
pericyte characteristic functions), and other genes are expressed in response to factors 
mediating endothelial–mural cell interactions. Though the issue needs to be clarified, 
one important question is whether MCAM/CD146 is involved in mural cells in 
microvascular districts of multiple tissues, since the known function of MCAM is to 
mediate interactions of MSC with other cells. Furthermore, BM-MSCs were reported to 
be involved in the formation of sinusoids, as opposed to capillaries, so it can be argued 
that a sinusoidal-type microvascular network was considered as a key developmental 
event in hematopoiesis233. 
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2. AIM OF THE THESIS 
 
 
The overall aim of this thesis is to investigate the role of MSCs and EPCs in 
decreasing acute rejection of pancreatic islet transplantation in a chemically induced rat 
model of type 1 diabetes. Previous studies based on the use of pancreatic islets alone 
and in combination with cell therapy confirmed that pancreatic islets alone are 
insufficient in re-establishing normoglycaemic levels due to their poor 
microvascularization in the resulting grafts. We therefore decided to perform pancreatic 
islet transplantation together with MSCs and EPCs, both of which were administered 
with pancreatic islets via the portal vein in syngeneic and allogeneic models in order to  
re-establish the normal architecture and function of pancreatic islets and reach 
normoglycaemic levels in the long-term. An assessment of the re-establishment of the 
revascularization and neoangiogenesis of the islets according to our protocols was then 
carried out using ex vivo molecular biology assays (RT-PCR). 
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3. MATERIALS AND METHODS 
 
3.1 Animals 
 
Inbred male Lewis (L) rats as recipients and Wistar Furth (WF), Lewis and 
Lewis LEW-Tg F455/Rrrc (Harlan) donor rats weighing approximately 250-300 g, were 
purchased from Charles River Laboratories, Calco, Italy. The animals were fed on 
standard rodent chow (Rieper, Italy) and water ad libitum; they were kept under a 12 h 
light/dark cycle. All the experimental procedures were carried out with the approval of 
the Ethical Committee for Animal Experimentation of the University of Pisa and the 
EEC/609/86. All efforts were made to reduce the number of animals used. 
 
 
3.2 Pancreatic Islets 
3.2.1 Pancreas isolation, digestion and islet culture  
 
Donor animals were anaesthetized with an intraperitoneal injection 
containing a single dose of Pentothal sodium (75 mg/Kg, Gellini International) and 
underwent a median laparotomy. The pancreas was highlighted and the bile duct was 
clamped at the duodenum point of release234, (figure 8 A).  
The bile duct was incanulated (figure 8 B) in proximity to the hepatic triad 
(portal vein, hepatic artery, bile duct) and the animal was sacrificed. The pancreas, 
distended by bile duct injection through a cannula with a diameter of 23 gauche, was 
perfused with 15 ml of Collagenase P, (Roche Diagnostics, Italy), 1 mg/ml maintained 
at T= + 4°C to avoid the activation of the enzyme. Collagenase P was able to disrupt the 
exocrine parenchyma, leaving the endocrine part intact, with a subsequent separation of 
the pancreatic islets.  
After the enzyme perfusion the pancreas resulted as being a well-defined 
organ so it was easily excised and minced. The pancreas was collected in a 50 ml tube 
and kept in ice until digestion started. The organ was incubated at T = + 37°C for 15 
min while being continuously shaken, so the Collagenase P was activated by heat, and 
at the end of the incubation time, the pancreas was  homogenized using a Pasteur's 
pipette.  
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The organ was washed with Hank’s solution (HBSS), centrifuged (300 g, 7 
min, T = + 4°C) and the solution above was discarded; the procedure was repeated three 
times (with these washing cycles, traces of fat and blood were removed with a parallel 
activation of Collagenase P). Islets were then separated from exocrine tissue by 
centrifugation on discontinuous gradient: the homogeneous tissue was resuspended in a 
tube containing 10 ml of Histopaque® 1119 (density: 1,119 g/l, Sigma, Italy) and then 
10 ml of Histopaque® 1077 (density 1,077 g/l, Sigma-Aldrich, Italy) and 10 ml of 
HBSS were stratified one after the other on the top of the sample. The tube was 
centrifuged for 20 min. at 546 g at T = + 4°C. The islets forming 2 rings were removed 
from the interface of the three layers, washed two-three times in HBSS, and finally 
resuspended in 10 mL of RPMI (Eurobio, Italy) supplemented with 10% Fetal Calf 
Serum (Eurobio, Italy), 1% L-glutamine (Biowest), 10 mM glucose (Baker Analized 
reagents, Netherlands), 50 U/ml penicillin (Sigma-Aldrich, Italy), 50 μg/ml 
streptomycin (Sigma-Aldrich, Italy), 0,2 μg/ml amphotericin B and 1% HEPES buffer 
(Sigma-Aldrich, Italy) on a free floating culture flask.  
Islets were handpicked under an inverted microscope, (figure 8 C), under 
sterile conditions and purity was assessed by Dithizone staining (Sigma-Aldrich, Italy). 
Pancreatic islets were cultured in RPMI medium (Eurobio, Italy) and incubated at T = + 
37 °C (95% air and 5% CO2), for a maximum time of two days before transplantation. 
The total islet mass, for each graft, expressed as the 150μm diameter islet equivalent 
number (IE), was calculated based on volumetric assumptions. 
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A      B 
 
C 
Figure 8. Pancreas isolation and islets culture. Clamping of bile duct at the duodenum point of release 
(A); incanulation of bile duct in proximity of the hepatic triad (B); pancreatic islets at optical microscope, 
magnification 10x, referred to a 100 μm scale bar (C). 
 
3.2.2 Pancreatic islet viability assay 
 
The number of viable islets was determined by a 0.4 % Trypan Blue staining 
assay (Sigma-Aldrich, Italy). The blue pigment did not enter the membrane of viable 
cells so they appeared as shiny, circular and  bright, with a dark side, (figure 9). The dye 
entered the non-intact membrane dead cells, so they became blue. After a cycle of 
centrifugation at 180 g for 5 min and a resuspension of the pellet in 1 ml of PBS-1X, the 
number of viable cells was determined by evaluating a 400 µl sample with 10 µl of 
Trypan Blue. Viable islets were evaluated under the optical microscope and only bright 
ones were counted.  
If less than 30% of the surface of the islet contained dead cells, the islet was 
considered viable because the visibly coloured surface means that there is a higher 
number of dead cells in the inner part of the islet. The cell count was completed within 
3 min to avoid the dye also entering the viable cells.  
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Figure 9. Islet viability by means of Trypan Blue.  
 
3.2.3 Islet quality assessment by Dithizone 
 
Dithizone (DTZ) (Sigma-Aldrich, Italy) was used to assess the functionality 
of pancreatic islet. DTZ binds zinc ions, which are necessary for insulin assembly in a 
resultant exameric structure, and are present in the islets’ ß cells, and therefore stains the 
islets red, (figure 10). Exocrine tissue, which the preparations also contain, does not 
bind DTZ and is therefore not stained235. Islets containing insulin-secreting ß cells were 
transplanted into animals with type 1 diabetes. Briefly, DTZ solution (0.1 mg/ml) in 
RPMI was filtered by a 0.2 µm filter and used to assess red stained viable islets.   
 
 
 
Figure 10. Islet staining with Dithizone. 
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3.3 Mesenchymal Stem Cells 
3.3.1 MSCs isolation, expansion and characterization  
 
Rat bone marrow cells were collected from tibiae and femurs of Wistar 
Furth, Lewis and  LEW-Tg (F455/Rrrc, University of Missoury, USA) animals 
according to Dobson's procedure236. Briefly, once the femurs and tibiae were extracted, 
their proximal ends were removed, and the bones were placed in microcentrifuge tubes 
supported by plastic inserts cut from 1 ml hypodermic needle casings and briefly 
centrifuged at 700 g for 2 min. The marrow pellet was resuspended in 10 ml of Hank’s 
balanced salts solution (HBSS, w/o calcium and magnesium; Euroclone, Milan, Italy) + 
1% fetal bovine serum (FBS, HyClone, South Logan, Utah, USA) and washed at 300g 
for 7 min. After the cells were passed through a 22-G needle, they were re-suspended in 
culture medium (DMEM-Low Glucose, with L-glutamine, 25 mM HEPES and 
pyruvate, GIBCO™–Invitrogen, Milan, Italy, supplemented with 10% FBS), counted 
using a hemocytometer and seeded in a 24 x 106/75 cm2 flask.  
Cells were incubated at T = + 37°C in a humidified atmosphere containing 
95% air and 5% CO2. Half of the complete medium was changed after 1 week and 
thereafter the whole medium every 3–4 days. When approximately 80% of the flask 
surface was covered, the adherent cells were incubated with 0.05% trypsin–0.02% 
EDTA (Eurobio, Courtaboeuf, Cedex B, France) for 5–10 min at T = + 37°C, harvested, 
washed with HBSS and 10% FBS, and resuspended in complete medium (primary 
culture, P0). Cells were then re-seeded at 104 cells/cm2 in 100-mm Ø dishes (P1): 
expansion of the cells was obtained with successive cycles of trypsinization and 
reseeding237. The number of colony forming units-fibroblasts (CFU-F) was used as a 
surrogate marker for MSC progenitors frequency: two 100-mm Ø dishes were seeded 
with 1 x 106 total nucleated cells. After incubation for 14 days at 37°C in a 5% CO2 
humidified atmosphere, the dishes were rinsed with HBSS, fixed with methanol and 
stained with Giemsa: visible colonies formed by 50 or more cells were counted and 
reported as the number of CFU-F/106 seeded Total Nucleated Cells (TNC)238. 
 
3.3.2 Immunophenotyping 
 
At the fourth or fifth passage, the morphologically homogeneous population 
of MSCs was analysed for the expression of particular cell surface molecules using flow 
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cytometric procedures: MSCs recovered from flasks by trypsin–EDTA treatment and 
washed in HBSS and 10% FBS were resuspended in a flow cytometry buffer consisting 
of CellWASH (0.1% sodium azide in PBS; Becton Dickinson, San Jose, CA, USA) with 
2% FBS. Aliquots (1.5 x 105 cells/100 µl) were incubated with the following conjugated 
monoclonal antibodies: CD45-CyChrome™, CD11b-FITC (in order to quantify 
hemopoietic-monocytic contamination), CD90-PE, CD106-PE, CD73-PE, CD54-FITC, 
CD44-FITC (BD Pharmingen, San Diego, CA, USA). Non-specific fluorescence and 
morphologic parameters of the cells were determined by incubation of the same cell 
aliquot with isotype-matched mouse monoclonal antibodies (Becton Dickinson, San 
Diego, CA, USA). All incubations were performed for 20 min, and after incubation the 
cells were washed and resuspended in 100 µl of CellWASH; 7-AAD (7-amino-
actinomycin D) was added in order to exclude dead cells from the analysis. Flow 
cytometric acquisition was performed by collecting 104 events on a FACScalibur 
(Becton Dickinson, San Jose, CA, USA) instrument and the data were analysed on 
DOT-PLOT bi-parametric diagrams using CELL QUESTpro software (Becton 
Dickinson, San Jose, CA, USA) on a Macintosh PC. 
 
3.3.3 Differentiation of MSCs 
 
The ability of MSCs to differentiate along osteogenic and adipogenic 
lineages was assayed, as described previously by Sbano et al355. Osteogenic and 
adipogenic differentiation were evaluated by cytochemical analysis. Petri dishes were 
stained to assess extracellular matrix mineral bound by Alizarin Red-S. Adipogenic 
differentiation was evaluated by staining lipid–rich vescicles with Oil Red O. 
 
3.3.4 Osteogenic differentiation 
 
The primary (P0) MSC culture was stimulated with osteogenic 
differentiating factors: 105 cells/plate were seeded in a 6 well-plate and cultured with 
the culture medium supplemented with 100 μg/ml Ascorbic Acid (Sigma-Aldrich, 
Italy), 10 mM β-Glycerophosphate (Sigma-Aldrich, Italy) and 10nM Dexamethasone 
(Sigma-Aldrich, Italy). The medium was replaced every 3 days and the deposition of 
mineral nodules was revealed after 20 days with Alizarin Red-S. The cells were washed 
with HBSS solution at room temperature and incubated at 4°C with 70% cold Ethanol 
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(T = - 20 °C) for 1 hour. They were then  washed twice with 1 ml of PBS 1X and  
incubated with Alizarin S, 40 mM, pH 4.2, (Sigma-Aldrich, Italy) at room temperature 
for 10 min while being continuously shaken. The cells were washed rapidly 5 times 
with HBSS to minimize the non-specific binding.  
 
3.3.5 Adipogeneic differentiation 
 
The primary (P0) MSC culture was stimulated with adipogenic 
differentiating factors: 105 cells/plate were seeded in a 6 well-plate and cultured in 
adipogenic medium (DMEM-LG with 10 % FBS, 0.5 mM of isobutyl methylxanthine, 
10 μM of dexamethasone, 10 μg/ml of insulin, and 70 μM of indomethacin; Sigma). 
The medium was replaced every 3 days and the accumulation of lipid-rich vacuoles was 
revealed after 21 days with Oil Red-O staining. The cells were washed with HBSS 
solution at room temperature and incubated at room temperature with 10% formalin for 
5 min; the formalin was then removed and the same volume of fresh formalin was 
added. The cells were incubated for 1 hour at room temperature. The formalin was then 
removed and the cells were washed with 60% isopropanol and left to dry. Subsequently, 
2.1 mg/ml Oil-Red O solution (Sigma-Aldrich, Italy) was added and incubated for 10 
min at room temperature to minimize the non-specific binding. The cells were washed 
four times with deionized H2O. 
 
 
3.4 Endothelial Progenitor Cells 
3.4.1 EPCs isolation and expansion 
 
Bone marrow was harvested from both femurs and tibias of Wistar Furth 
and Lewis LEW-Tg (EPCs GFP+) F455/Rrrc (Rrrc, University of Missoury, USA) 
male rats, according to Dobson’s procedure239. Mononuclear cells (MNC) were 
obtained by density gradient centrifugation. The cells, 25x106 MNC/well, were then 
seeded on 6 well plates coated with 1% Gelatin (Sigma-Aldrich, Italy), and cultured 
in EGM2 (Lonza, Italy) supplemented with 10% FBS. They were then  incubated at 
37°C in a fully humidified atmosphere containing 95% air and 5% CO2. EPC 
colonies appeared in cell cultures after 1 week and were identified as circumvented 
monolayers of cobblestone-like cells. 
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3.4.2 Flow cytometric assay 
 
A flow cytometric analysis was performed on cells at the passage P2 
using the following surface antibodies: CD45 (in order to quantify hemopoietic–
monocytic contamination), CD44, CD90, CD31, Endothelium (AbD Serotec, BD 
Pharmingen). Non-specific fluorescence and morphologic parameters of the cells 
were determined by isotype-matched mouse monoclonal antibodies and 7-AAD. The 
cells were measured in a FACSCalibur (Becton Dickinson) flow cytometer. 
 
3.4.3 Dil-AC-LDL uptake 
 
To identify ex vivo expanded EPC the cells were imaged for their 
incorporation of acetylated low-density lipoprotein (aLDL) labelled with fluorescent 
Dil dye (Dil-Ac-LDL, Invitrogen). The cells were incubated with 10 μg/ml Dil-Ac-
LDL for 4 hours at 37°C on a glass slide. After fixation with 10% formalin for 20 
min at 4°C, they were washed and visualized by fluorescence microscopy. 
 
 
3.5 In vitro experiments 
3.5.1 In vitro angiogenesis assay 
 
BD Matrigel™ Basement Membrane Matrix was thawed on ice overnight, 
and a volume of 50 µL, added to EGM-2 (Lonza, Italy) supplemented with 1% FCS was 
spread evenly over each well of a 24-well plate. The plates were incubated for 30 min at 
37°C to allow Matrigel to gel. EPCs GFP+ were seeded (3.0 x 104 cells/cm2) in 
complete absence of light and cultured in 1 ml of EGM-2 medium (Lonza, Italy)  
supplemented with 1% FCS. After 2 hours of incubation at 37°C, the cultures were 
photographed (5 fields for each well: the four quadrants and the center) at a 
magnification of 10 x, and were checked approximately every 2 hours to observe the 
tube formation. Phase contrast (bright field) and fluorescence images were recorded by 
carrying out a double channel experiment with a Carl Zeiss Microscope with a 
fluorescence camera, (AxioVision 4.8.2 software).   
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3.5.2 Monitoring cell growth rate 
 
The proliferation rate of MSCs and EPCs was assessed by separate assays. 
The cells, MSCs or EPCs, were seeded as previously mentioned and, after the 
attachment of the cells, they were removed by trypsinization at 24, 48 and 72 hours to 
determine their growth rate. The cells were counted in a Thoma’s camera under an 
optical microscope and fluorescence microscope. 
Each doubling time (Td) was calculated, by assuming a constant growth rate, 
with the following formula:  
Td= (t1-t0)*ln2/ln(q1/q0) 
 
where q0 is the cell number at time t0 and q1 is the cell number at time t1. 
  
 
3.6 In vivo experiments 
 
Recipient animals received a single high dose (65mg/kg intraperitoneal) 
of  Streptozotocin (STZ) (Sigma-Aldrich, Italy). Streptozotocin is an antibiotic 
extracted from Streptomyces achromogenes and 10 hours after the injection it causes 
pancreatic beta cells necrosis, with high levels of insulin and hypoglycaemia240. 
Blood glucose concentration was determined by using a commercially 
available glucose meter on days 3 and 5 after STZ injection (Stat Strip XPress™, 
Nova Biomedical UK). Animals with fasting blood glucose higher than 16.7 mmol/l 
(> 300 mg/dl), on at least two consecutive measures, were considered diabetic, while 
rats whose blood glucose remained lower than 16.7 mmol/l after 1 week were 
withdrawn from the study. 
Donor animals were anaesthetized with an intraperitoneal single dose of 
Penthotal Sodium, 65 mg/kg, (Gellini international), while diabetic recipients were 
anaesthetized with an intraperitoneal dose 0.3 ml of Zoletil 100 (tiletamin 90 mg/Kg 
and zolazepam 10 mg/Kg, Virbac s.r.l., Italy, intraperitoneal) and the portal vein was 
exposed through a midline incision under the spine. All animals were transplanted 
either with IE or MSCs or EPCs via the portal vein of the liver. 
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3.6.1 Experimental Transplant groups 
 
Control group 
? 700 IE L-L (n=6) 
? 700 IE WF-L (n=5) 
? 500,000 EPCs WF-L (n=4) 
MSCs group 
? 700 IE L-L + 500,000 MSCs (n=6) 
EPCs group 
? 700 IE L-L + 500,000 EPCs (n=11) 
? 700 IE WF-L + 500,000 EPCs (n=5) 
 
3.6.2 Pancreatic islet, MSCs and EPCs transplantation 
 
Pancreatic islet  transplantation 
Pancreatic islets were collected from the cultured flasks and transferred to a 
sterile tube. After being  centrifuged at 180 g for 5 min, the pellet was suspended in 0.5 
ml of PBS-1X, counted and suspended again in 0.5 ml of PBS-1X for the injection. 
Mesenchymal Stem Cells transplantation 
MSCs medium was removed from the flasks and treated with a cycle of 
Trypsin 1X with 7 min of incubation at T = + 37°C, 5 % CO2, to let the enzyme 
activate. The cells were then blocked by DMEM; the resultant solutions were collected 
and centrifuged at 180 g for 5 min. The pellet was suspended in 0.2 ml of PBS-1X 
solution, of which an aliquot of 30 µl was taken and added to 30 µl of Trypan Blue and 
counted in Thoma’s camera to assess viable cells. 
Endothelial Progenitor Cells transplantation  
EPCs medium was removed from the flasks and treated with a cycle of 
Trypsin 1X with 5 min of incubation at T = + 37°C, 5 % CO2, to let the enzyme 
activate. The cells were then blocked by HBSS supplemented with 10% FCS; the 
resultant solution was collected and centrifuged at 180 g for 5 min. The pellet was 
suspended in 0.2 ml of PBS-1X solution, of which an aliquot of 30 µl was taken and 
added to 30 µl of Trypan Blue and counted in Thoma’s camera to assess viable cells. 
Once the cells MSCs or EPCs were counted and placed, either alone or in 
combination with pancreatic islets, in 0.5 ml of PBS-1X solution. When the cells were 
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injected with pancreatic islets, they were mixed together in the solution and incubated 
for one hour maximum at T = + 37°C, 5 % CO2. 
After a median laparotomy and a midline incision, the portal vein was 
exposed, (figure 11 A) and cells were injected using a syringe (the portal vein was the 
site of injection where the cells were allowed to enter the hepatic parenchyma), (figure 
11 B). 
 
 
 
 
 
 
 
 
    A       B 
Figure 11. Portal vein islet transplantation. The portal vein was exposed through a midline incision 
under the spine (A). Islets were suspended in 0,5 mL of PBS solution and injected through a 26G needle 
into the portal vein (B). 
 
After having padded the site of injection and washed the animal entrails with 
physiological solution, the abdomen wall was sutured at two different edges. The inner 
edge, made up of muscles and peritoneum, was sutured with a 4-0 gutstring (Ethicon, 
Johnson & Johnson); the upper edge was also sutured with a non-reabsorbable gutstring 
(Ethicon, Johnson & Johnson). The animals were kept in separate cages and checked 
daily for glucose monitoring in accordance with the Ethical Committee guidelines of the 
University of Pisa.   
 
 
3.7 Assessment of Graft Function 
 
Fasting blood glucose levels were used to assess islet graft function. The 
measures were performed at defined time points (-5, -3, 0, 2, 3, 4, 5, 7, 9, 12, 15, 18, 
21, 24, 27, 30, 37, 44, 51, 58, 72, 86, 100, 120, 140, 160, 180 days from 
transplantation). Graft failure was defined as a reversal of hyperglycemia (> 300 
mg/dL) by two consecutive measurements by using a glucometer. 
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3.8 Intraperitoneal glucose tolerance test (IPGTT) 
 
After 6 h of fasting, the animals of all the groups were injected 
intraperitoneally with 2 g/Kg body weight of Glucose solution (Baker Analized, 
Reagent). Their blood glucose levels were measured at 0, 15, 30, 60, 90 and 120 
minutes after the injection using a glucometer. The values were compared to diabetic 
and healthy control animals. 
 
 
3.9 Ex vivo experiments  
 
A maximum amount of 30 mg of fresh liver tissue was collected in a 
microcentrifuge tube and stored at T = + 4 °C immediately after excision of the 
organs and up to 2 hours before starting with the purification of total RNA. If it was 
not possible to process the tissue within 2 hours, the samples were stored at T = - 80 
° C. 
 
3.9.1 Total RNA extraction and characterization 
 
Once the samples of the liver tissues were weighed as above, disrupted 
and homogenized by a syringe in 600 μl of the lysis RLT buffer supplied with β-
Mercaptoethanol (a highly denaturing guanidine-thiocyanate–containing buffer, able 
to immediately inactivates RNases to ensure purification of intact RNA) and 
incubated for 15 min at room temperature, total RNA was extracted using the 
RNeasy® Mini kit following manufacturer’s ‘Purification of total RNA from animal 
tissues’ protocol (see the RNeasy Mini Handbook, Qiagen, Hilden, Germany, 
http://www.qiagen.com).  
Briefly, the lysate was centrifuged for 3 min at full speed; the supernatant 
was carefully removed by pipetting and transferred to a new microcentrifuge tube. 
Moreover, one volume of 50% ethanol was added to the cleared lysate and mixed 
immediately by pipetting, with no further centrifugation (ethanol was added to 
provide appropriate binding conditions). 
Afterwards up to 700 μl of the sample was transferred to an RNeasy spin 
column placed in a 2 ml collection tube and centrifuge for 15 s at 12000 g. The flow-
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through was discarded and exceeding volume was re-transferred in the same RNeasy 
spin column and centrifuged again at the same conditions (the step in the RNeasy 
Mini spin column allows the total RNA to bind to the membrane, while contaminants 
were efficiently washed away). An amount of 350 μl of Buffer RW1 was added to 
the RNeasy spin column and centrifuged for 15 s at 12000 g to wash the spin column 
membrane. In order to degrade genomic DNA from RNA preparation prior to RT-
PCR, the column was added with 46 μl of the following mix:  
- 5 μl Incubation Buffer 10x (Roche Diagnostics GmbH, Germany, www.roche.com) 
- 1 μl Recombinant DNase I RNase-free 10,000 units (Roche Diagnostics GmbH, 
Germany, www.roche.com)  
- 40 μl Rnase-free water.  
The spin column was incubated with the mix for 30 min at room 
temperature and at the end of the incubation time, buffer RW1 process was repeated 
with the same conditions as before DNase treatment. After centrifugation, the 
RNeasy spin column was carefully removed from the collection tube so that the 
column did not contact the flow-through. It was then added 500 μl of buffer RPE 
supplied with ethanol to the RNeasy spin column and centrifuged for 15 s at 12000 g 
to wash the spin column membrane. The flow-through was discarded and this step 
was repeated with a final centrifugation for 2 minutes at 12000 g (this long 
centrifugation dries the spin column membrane, ensuring that no ethanol was carried 
over during RNA elution, because residual ethanol might interfere with downstream 
reactions).  
The RNeasy spin column was placed in a new 2 ml collection tube and 
centrifuged at full speed for 1 min to eliminate any possible carryover of Buffer 
RPE, or if residual flow-through remained on the outside of the RNeasy spin column 
after previous step.  
The RNeasy spin column was placed in a new 1.5 ml collection tube, added with 40 
μl RNase-free water directly to the spin column membrane and centrifuged for 1 min 
at 12000 g to elute the RNA. 
The amount of extracted RNA was quantified by measuring the 
absorbance at λ = 260 nm with a Biophotometer Plus Eppendorf spectrophotometer 
diluted as follows: 5 µl RNA + 95 µl RNase free water. The final concentration of 
the RNA was expressed in ng/μl. The purity of RNA was checked by measuring the 
ratio of the absorbance at 260 and 280 nm where a ratio ranging from 1.5-2.0 was 
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considered to be pure. The absence of degradation of the RNA was confirmed by 
RNA electrophoresis on a 1.5% agarose gel containing ethidium bromide.  
 
3.9.2 Reverse transcription 
 
To synthesize first strand cDNA, RNA was reserve transcribed with 
RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, Life sciences): the kit 
provides a complete system for efficient synthesis of first strand cDNA from mRNA 
or total RNA templates.  
Briefly, in a sterile, nuclease-free tube on ice, a variable amount of total 
RNA, between 0,1 ng and 5 μg, was added; in the tube was placed a fixed amount of 
oligo(dT)18 primer (1 μl), (the oligo(dT) primer selectively anneals to the 3’-end of 
poly(A) RNA, synthesizing cDNA only from poly(A) tailed mRNA). In the same 
tube a variable content of nuclease-free water was added up to a final volume of 12 
μl. After a gentle mix by pipetting, the sample was briefly centrifuged and incubated 
at 65°C for 5 min and maintained on ice.  
At the end of the incubation period, the mix was added with the 
following:  
- 4 μl of 5X reaction buffer 
- 1 μl of RiboLock™ RNase Inhibitor (20 u/μl) (protect effectively RNA from 
degradation at temperatures up to 55°C) 
- 2 μl of 10 mM dNTP Mix 
- 1 μl of RevertAid™ M-MuLV Reverse Transcriptase (200 u/μl) (maintains activity 
at 42-50°C) 
up to a total volume of 20 μl.  
After a gently mixing and centrifugation, the sample was incubated for 60 
min at 42°C. The reaction stops after heating at 70°C for 5 min. The reverse 
transcription reaction product could be directly used in PCR applications or 
aliquoted in equal volumes and stored at T = - 80 °C for several months. 
cDNA was quantified by measuring the absorbance at λ = 260 nm with a 
Biophotometer Plus Eppendorf spectrophotometer with the following dilution: 1 µl 
cDNA + 99 µl water. The final concentration of the cDNA was expressed in ng/ml.  
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3.9.3 Real-time quantitative RT-PCR 
 
Real-time quantitative RT-PCR (qRT-PCR) was performed with SYBR 
Green Master Mix technique (Qiagen), according to the manufacturer’s instructions.  
A total volume of 5 µl of RNA was used in the assay for each sample and 
all the genes were tested with the same panel of cDNA samples. All standards and 
samples were run in triplicate on 96-well reaction plates with the iQTM5 Multicolor 
Real-Time PCR Detection System (Bio-Rad).  
Reactions were prepared in a total volume of 25 µl containing 5 µl 
volume cDNA, 1 µl of each primer (forward and reverse 10 µM), 12.5 µl of SYBR 
Green master mix, 5.5 µl of sterile water. No template controls were run for each 
master mix and primer pair.  
After having performed preliminary gradient real-time RT-PCR assays, 
the optimal annealing temperature for all the primer pairs resulted to be T = + 60 °C. 
At this temperature cycle threshold (Ct) value was generated as well as a sharp 
melting peak, with no amplification of non-specific products or primer-dimer 
artefacts. The conditions of reverse transcription and primer concentrations were set 
according to the recommendations in the manufacturer’s instructions. PCR 
efficiencies were calculated with a relative standard curve using serial 1:5 dilutions 
of template cDNA in triplicate. Gene expression variation was calculated for 
individual reference genes based on Ct values, correlation coefficient (R2), real-time 
PCR efficiencies (E) and slope values, generated of each standard curve. The curves 
obtained for each cell line showed a linear relationship between RNA concentration 
and the Ct value of PCR real time for all genes. Real time efficiency E was 
calculated from the given slopes in the iQ Real Time PCR System software 
according to the equation: E=10-(1/b)-1, where b is the regression coefficient. 
Efficiency of primers pairs ranged from 90% to 120% and correlation coefficient 
ranged from 0.993% to 1.0%. 
The real time amplifications included 3 minutes at T = 96 °C (AmpliTaq 
Gold activation), followed by 40 cycles at T = 96 °C for 30 seconds and at T = 60 °C 
for 1 minute. This cycle was followed by a melting curve analysis, ranging from 
55°C to 95°C, with increasing steps of temperature of 1°C every 30 seconds.  
 75
Baseline and threshold values were automatically determined for all 
plates using the Bio-Rad iQ5 Software 2.0. The threshold value has been 
subsequently manually set if necessary. 
When comparing gene expression in different samples, it is essential to 
consider experimental variations such as amount of starting material, inhibitory 
factors of the tissue, RNA extraction and integrity, reverse transcription efficiencies, 
loading error. To account for these, accuracy of RT-PCR relies on normalization to 
an internal control, often referred to a reference gene (RG). Before any gene is 
chosen as a reference, an exhaustive search is necessary to ensure that no significant 
regulation occurs.  
The expression of the primers VEGF-A, ANG-1, VCAM-1, SDF-1, 
PECAM-1 for RT-PCR was designed using Beacon Designer software. The primer 
for the reference genes, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
also designed using the same software. This procedure has been standardized taking 
into account the particular structural characteristics that the primers could be due to 
the chemistry of the SYBR-Green. The aim was to get similar temperatures to 
perform more analysis at the same time. Special attention was given to primer 
length, annealing temperature, base composition and 3’-end stability. Exon and 
intron boundaries were determined by aligning primers with corresponding rat 
genomic sequences downloaded from GenBank, 
http://www.ncbi.nlm.nih.gov/genbank/, and ensuring the specificity of the sequence 
by BLAST. 
Sequences of the primers: 
SDF-1               TGCATCAGTGACGGTAAGCCA (F) 
 GATCCAAGAGTACCTGGACAA (R) 
PECAM-1  TCAGCTGCCAGTCAGTAA ATGG (F)  
 TCTGGAAGTTGCTCTTTGCTCTT (R) 
VEGF-A GAGGAAAGGGAAAGGGTCAAAA (F) 
 
 AATCCTGGAGCGTTCACTGTG (R) 
ANG-1 GTGGCTGGAAAAACTTGAGA (F) 
 ACATCCCGTCTTGAAATCCA (R) 
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3.10 Statistical analysis and image performing 
 
Data were analyzed using GraphPad Prism version 5 software. All numerical 
data were expressed as the mean ± SE. Data were tested for statistical significance with 
the paired Student's t test, the unpaired Student's t test or by analysis of variance (one-
way ANOVA), as appropriate. When significant differences were observed, the Tukey 
test as a post hoc comparison test (one-way ANOVA) was done. A value of p < 0.05 
was considered significant. 
Analysis of MSC and EPC samples was realized by flow cytometry with a 
FACScan (Becton Dickinson, argon laser source, with wave length of emission at 488 
nm and power of emission 15 mW) on a PC by CELL QUEST software (Becton 
Dickinson). 
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4. RESULTS 
 
4.1 In vitro experiments 
4.1.1 Expansion and characterization of rat MSCs 
 
Rat BM-derived MSCs were successfully culture-expanded. Cells were 
particularly heterogeneous until the fourth–fifth passage in culture and also comprised 
numerous lipid vacuoles.  Haematopoietic cells were lost during the medium changes as 
shown by Flow cytometric analysis. Primary culture cells were trypsinised and plated, 
reaching a cellular expansion up to a mean 109 factor in 3 months (Figure 12 A). The 
time of proliferation of MSCs was represented in fig. 1A, showing a mean value of 
doubling time of 25 hours. 
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Figure 12. Characteristics of MSCs. Doubling time of MSCs represented as the growth curve (A); 
typical morphology in time lapse in the first 10 days from the seeding (B). 
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After the fifth passage, the cells grew exponentially, requiring weekly 
passages (Figure 12 B). The CFU-F assay was used as a surrogate assay for MSCs. In 
the BM total nucleated cell population, the estimated CFU mean count resulted as 
56/106 TNCs.  
Isolated cells from bone marrow of Lewis rats showed, by carrying out a 
careful study with FACS analysis, a homologous dimensional distribution in the range 
300-800 μm, (figure 13 A). Cells resulted negative for isotype control (figure 13 C) 
because they did not bind non-characteristic and non-autofluorescent antibodies. 
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Figure 13. Distribution of MSCs. Distribution according to the measure of the population of isolated 
cells (A), viability analysis with 7-AAD (B); isotype control with mouse IgG1 (C). 
 
 
FACS analysis was also used to assess the purity of our MSCs and the 
existence of a homogeneous population of adherent cells (after 4–5 passages). After the 
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Mouse IgG1 FITC  
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exclusion of dead cells, (R1 on 7-AAD negative elements; cells positive to 7-AAD were 
excluded because they could give a cross-reaction with non-specific antigens, figure 13 
B) the cell population resulted as being uniform positive for CD90, CD44, CD54, 
CD73, and CD106. There was no significant contamination of haematopoietic cells, as 
Flow cytometry assay was negative for markers of haematopoietic lineage, including 
CD11b and CD45, (figure 14). 
MSC WF K 20/04/09.004
100 101 102 103 104
CD90 PE
MSC WF K 20/04/09.003
100 101 102 103 104
CD106 PE  
MSC WF K 20/04/09.002
100 101 102 103 104
CD11B FITC
MSC WF K 20/04/09.005
100 101 102 103 104
CD45 PerCP  
Figure 14. Flow cytometric analysis of MSCs. CD11b and CD45 antibodies showed no contamination 
of haematopoietic cells but positivity for classical mesenchymal markers CD44, CD54, CD73, CD90, 
CD106. 
 
MSCs treated with osteogenic medium formed small deposits of 
hydroxyapatite stained intensely red with Alizarin S, (figure 15 A). MSCs treated with 
adipogenic medium were successfully differentiated towards adipogenic lineages: lipid 
vacuoles started to accumulate in the cytoplasm of the cells after just 2–3 days of 
stimulation and were stained orange–red after 21 days (figure 15 B). 
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Figure 15. Differentiation of MSCs. Osteocytes, with visible deposits of hydroxyapatite intensely 
stained red by means of Alizarin S, (A), and orange–red stained lipid vacuoles of the cytoplasm of MSCs 
treated with adipogenic medium with Oil-Red O, (B). 
 
 
4.1.2 Expansion and characterisation of rat EPCs 
 
We cultured-expanded rat BM-induced EPCs from Wistar Furth and Lewis 
EGFP rats. 
Confluent EPCs (after 14 days) showed spindle-shaped cells; primary culture cells (14 
days) were trypsinized and plated, reaching a mean cellular expansion of up to 106 at P1 
(range 105–107). EPCs used to perform our transplants were EPC WF POOL AG clones. 
EPCs time of proliferation was represented in figure 16, showing a mean 
value of doubling time of 27 hours. 
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Figure 16. Doubling time of EPCs. Doubling time represented as the growth curve of EPCs.  
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Flow cytometry was used to assess the purity of EPCs and analyze the 
surface markers of mesenchymal, hematopoietic and endothelial lines (CD45, CD44, 
CD90, CD11b, CD31, Endothelium). Isolated EPCs resulted positive for CD44, CD90, 
(figure 17 A), Endothelium (ox43 protein expressed on vascular endothelial cells in 
each rat tissue), (figure 17 B). Low levels of CD31, typical of mature endothelial cells 
and the markers of the hematopoietic line, (CD45, CD11b), were found (figure 17 C). 
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Figure 17. Flow cytometric analysis of EPCs. Expression of CD44 (A), CD90 (A), Endothelium (B), 7-
AAD markers (B); total phenotypic characterization of EPCs (C). 
 
 
The functional characterization of endothelial progenitors was obtained by 
means of an encapsulation test of ac-LDL-dil (Acetilated-Low density lipoprotein-dil) 
in immunofluorescence (figure 18). 
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Figure 18. ac-LDL-dil (Acetilated-Low density lipoprotein-dil) immunofluorescence test. Acetylated 
lipoprotein complex (red) is visible inside the cells. 
 
4.1.3 Assessment of angiogenic properties of EPCs 
The angiogenic ability of EPCs was assessed using an in vitro endothelial 
tube-formation assay. We performed a time-lapse experiment to investigate the 
formation of capillary-like structures by evaluating their growth within the first 12 
hours after seeding. The first 6 hours were followed by an evaluation of EPCs GFP+ 
which demonstrated that EPCs can grow from a low percentage of scattered capillaries 
(two hours after seeding, figure 19 A) to a gradually more organized structure in 
discrete matrigel regions (four hours after seeding, figure 19 B). Finally EPCs GFP+ 
showed an ability to organize themselves successfully in regions similar to tubular 
structures (six hours after seeding, figure 19 C). A parallel experiment was conducted 
only in the bright field and showed, 12 hours from after seeding onto BD Matrigel™ 
Basement Membrane Matrix, the highest capacity of EPCs to form capillary-like 
structures (figure 19 D).     
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Figure 19. Time lapse of EPCs onto BD Matrigel™ Basement. EPCs GFP+, shown in both bright field 
and fluorescent images, grow gradually from a sparsely scattered capillary structure (2 hours after 
seeding, A) to a more organized (4 hours after seeding, B) and finally to one similar to tubular structure (6 
hours after seeding, C). After 12 hours onto matrigel, EPCs show an excellent ability to grow in a 
complete capillary-like structure (bright field, D). 
 
4.2 In vivo experiments 
Islet transplants were performed in an experimental animal (rat) model in 
which diabetes was chemically induced by means of a single high dose of 
Streptozotocin (STZ). Streptozotocin, a glucosamine-nitrosourea (a DNA alkylating 
agent that enters cells exclusively via the GLUT2 glucose transport protein), is a 
diabetogenic compound that is especially toxic to pancreatic islet insulin-producing β-
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cells. Chemically induced diabetes is comparable to type 1 Diabetes because most of the 
β-cells in the pancreatic islets are disrupted.  
Syngeneic transplantations were carried out by using Lewis donors and by 
injecting the islets into Lewis recipients, whereas for allogeneic transplants we used 
Wistar Furth rats as donors and we implanted the islets into Lewis recipients.  
All the animals used derived from inbred strains, created by crossing male 
and female siblings. The inbred offspring of this cross are again mated with each other 
and then again for 20 consecutive generations: the result of this manipulation is a 
population of animals in which only one allele of every gene is present; consequently, 
all animals within an inbred strain are genetically identical, akin to identical twins.   
In our model a marginal mass of pancreatic islets was chosen as the 
minimum dose to be infused in the animals in order to decrease the blood glucose 
without reaching normoglycemic levels. In this context, 700 islets equivalents (IE) 
compared with 1400 IE, either syngeneic or allogeneic and transplanted in the portal 
vein of the animals, resulted in a rapid decrease in glycaemic levels: the time required 
for this decrease was short but not enough to re-establish normoglycaemic levels. For 
this reason 700 IE was chosen as the marginal mass to be transplanted alone or in 
combination with cell therapy in order to assess grafted islet viability and functionality. 
 
4.2.1 Portal vein syngeneic and allogeneic transplantation of 700 IE 
 
The syngeneic transplantation of a marginal mass of 700 Lewis pancreatic 
islets in the portal vein of diabetic Lewis rats induced a fast decrease in blood glucose, 
which returned to high levels (n=6) within twelve days. The values remained strongly 
significant until the twelfth day after transplantation (** p<0.01 day 3, 12 vs. day 0; *** 
p<0.001 day 5, 7 vs. day 0) with a continuous growth towards diabetic levels up to day 
15, (figure 20, green line).  
The group of 700 IE WF allogeneic transplanted (n=5) in Lewis rats showed 
a similar trend to the previous syngeneic, but the levels returned to high values 9 days 
after transplant. Indeed, the decrease in blood glucose levels and the return to diabetic 
values were more homogeneous than the syngeneic transplants. These levels were as 
strongly significant as the previous ones, but only up to day 7 (*** p<0.001 day 3, 5, 7 
vs. day 0). However, the levels did not maintain their significance until the end of the 
monitoring time (figure 20, orange line).  
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There were no further significant values between day 15 of the syngeneic 
transplants and day 15 of the allogeneic transplants.  
The animals which received 700 IE (either syngeneic or allogeneic) 
continued to be monitored even after 15 days, but as the glycaemic levels did not 
decrease, the animals were sacrificed 30 days after transplantation.   
The allogeneic transplants showed worse results than the syngeneic 
transplants in maintaining glucose control also in the early period after transplantation.  
 
 
Figure 20. Comparison between the curves relative to 700 IE syngeneic and 700 IE allogeneic 
transplants. The two groups show the same major significant levels in the first week after transplantation 
(*** p<0.001 day 7 vs. day 0 either for syngeneic or allogeneic group); 15 days after transplantation 
neither the syngeneic (green line) nor the allogeneic group (orange line) shows a significant decrease 
compared to the day of transplant. 
 
4.2.2 Portal vein allogeneic transplantation of 500,000 EPCs alone  
 
To evaluate the effect of administration of EPCs alone on blood glucose 
levels, an allogeneic model of transplant with a single dose of 500,000 EPCs WF was 
performed in the portal vein of diabetic-induced Lewis rats.  
The glucose monitoring pattern was non-homogeneous, in fact the decrease 
in levels was fast in the early post-transplant period; this trend did not continue over 
time and rather showed a discontinuous growth towards diabetic levels from the fourth 
day after the transplant onwards.  
Blood glucose levels decreased with a very significant value only at day 3 
(** p<0.01 day 3 vs. day 0), while one week after transplantation the significance was 
further decreased (* p<0.05 day 7 vs. day 0), (figure 21), and after this period blood 
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glucose levels returned to diabetic values. It is worth noting that in this pattern the 
reported levels showed high values of standard error, in correspondence with low 
significant levels.  
The animals were monitored for 30 days after transplantation because, in addition to 
showing no positive trend in the blood glucose levels, they gradually lost their body 
mass and were therefore sacrificed. 
 
Figure 21. Allogeneic transplantation with 500,000 EPCs. Animals were transplanted with 500,000 
EPCs WF in the allogeneic model. The trend was not homogeneous and the blood glucose levels showed 
a significant decrease three days after transplantation (** p<0.01 day 3 vs. day 0) and a slight decrease 
seven days after transplantation (* p<0.05 day 7 vs. day 0). 
 
4.2.3 Portal vein syngeneic and allogeneic transplantation of 700 IE + 500,000 EPCs 
 
In both a syngeneic and allogeneic model of a marginal dose of pancreatic 
islets, we studied two groups of animals which had received 500,000 EPCs in the portal 
vein. 
The animals were checked over a duration of 180 days for the syngeneic 
group, and over a duration of 75 days for the allogeneic group. 
The trends of the glycaemic levels of both syngeneic and allogeneic groups 
compared with the 700 IE alone, respectively were shown in figure 22 A and 22 B. 
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Figure 22. Transplantation with 700 IE + 500,000 EPCs.  Glycaemic levels of syngeneic 700 IE L-L 
compared with syngeneic 700 IE + 500,000 EPCs (A) Islets alone show a return to diabetic values within 
15 days after transplantation, even though the trend shows statistically significant points (green line, ** 
p<0.01 day 3 vs. day 0, *** p<0.001 days 5, 7 vs. day 0). The syngeneic transplants with 700 IE + 
500,000 EPCs (red curve) show a considerable decrease in blood glucose values linked to continuous 
extremely significant levels within the first 15 days after the transplant (*** p<0.001 days 3, 5, 7, 15 vs. 
day 0). There is an extremely significant difference on the fifteenth day between 700 IE alone and islets 
plus cell therapy (*** p<0.001 day 15 700 IE vs. day 15 700 IE + 500,000 EPCs). Glycaemic levels of 
allogeneic 700 IE WF-L compared with allogeneic 700 IE + 500,000 EPCs (B) The trend of 700 IE islets 
alone (orange line) shows an increase, after the early decrease in blood glucose levels, just 9 days after 
transplantation. This decrease shows a good pattern in the first week (*** p<0.001 days 3, 5, 7 vs. day 0), 
but the levels return to diabetic levels after that time point. The curve relative to allogeneic transplants 
700 IE + 500,000 EPCs (blue line) shows a non-homogeneous decrease in the first 15 days, the glycaemic 
levels show statistically significant values (*** p<0.001 days 3, 5, 7, 12 vs. day 0) and remain under the 
diabetic threshold.  
 
In figure 22 A it was shown a comparison between animals which had 
received 700 IE plus 500,000 EPCs syngeneic transplant (red line) and the 
corresponding syngeneic 700 islets alone treatment (green line).  
The group of animals transplanted with syngeneic 700 IE showed a decrease 
in glycaemic levels in the early days post-transplant, but the values returned to diabetic 
ones even though they show statistically significant points in the first 15 days (** 
p<0.01 day 3 vs. day 0, *** p<0.001 day 5, 7 vs. day 0). The group with syngeneic 700 
IE + 500,000 EPCs showed a faster decrease in glucose levels than 700 IE alone, within 
15 days after transplantation and the values remained statistically significant during this 
period of time (*** p<0.001 day 3, 5, 7, 15 vs. day 0).  
The glycaemic levels of the islets plus cell therapy remained largely under 
the diabetic threshold value in the first 15 days and its curve also showed very little 
range of standard errors mostly from day 7 onwards, maybe due to the high number of 
treated animals (n=11).  
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It is to note an extremely significant difference between glycaemic levels of 
the two groups on the fifteenth day (*** p<0.001 day 15 syngeneic vs. day 15  
allogeneic). 
In figure 22 B it was shown a comparison between 700 IE alone (orange 
line) and 700 IE + 500,000 EPCs (blue line), both allogeneic. The group of animals 
transplanted with allogeneic 700 IE showed an increase, followed by the early decrease 
in blood glucose levels, just 9 days after transplantation. The values, in fact, showed 
statistically significant points only within 9 days post transplantation (*** p<0.001 day 
3, 5, 7 vs. day 0). The curve of 700 IE + 500,000 EPCs showed a decrease within a 
period of 7 days and a slight increase followed by a further decrease within a period of 
15 days.  
Both curves showed extremely significant values in the first week following 
the transplant (*** p<0.001 day 3, 5, 7 vs. day 0), but, compared with 700 IE alone, the 
curve relative to islets plus cell therapy showed a further statistically significant level on 
day 12 (*** p<0.001 vs. day 0). Furthermore, the glycaemic levels remain under the 
diabetic threshold in the first two weeks after transplantation.  
On day 15 there was no statistically significant difference between the values 
of the two curves. It is interesting to note that both curves referring to the islets plus cell 
treatment, either syngeneic or allogeneic, followed the same trend as the islets alone, but 
the curves relative to 700 IE + 500,000 EPCs remain under the diabetic threshold (300 
mg/dl), while the curves relative to 700 IE alone return to diabetic values within 15 
days.      
The curves relative to cell therapies (syngeneic vs. allogeneic) were 
compared from day 15 to day 70 after transplantation, as shown in figure 23 A.  
The animals receiving a syngeneic transplant show continuous statistically 
significant values until day 70 and blood glucose levels remain largely under the 
threshold value of 300 mg/dl (*** p<0.001 day 30, 45, 60, 70 vs. day 0). 
On the other hand, the allogeneic trend showed extremely significant values 
only up to day 45 (*** p<0.001 day 30, 45 vs. day 0) and the glycaemic levels returned 
to high values from day 60 onwards, therefore the animals were sacrificed 70 days after 
transplantation. When comparing both curves there are very significant levels only in 
the last two points (** p<0.01 day 60, 70 syngeneic vs. day 60, 70 allogeneic).   
The syngeneic curve of 700 IE + 500,000 EPCs was observed for longer  
than the allogeneic one with the monitoring period continuing up to 180 days after 
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transplantation. The trend of the curve is quite homogeneous, in fact there was little 
standard error for all of the monitoring period in addition to extremely significant values 
(*** p<0.001 day 90, 120 and 180 vs. day 0). Worth noting are the very low glycaemic 
levels until 6 months after transplant, which were even lower than 200 mg/dl, (figure 23 
B).  
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Figure 23. Comparison of syngeneic and allogeneic trends in the long-term. Comparison of syngeneic 
and allogeneic transplantation curves from 15 to 70 days after transplantation (A). The syngeneic 
transplants with 700 IE + 500,000 EPC (red curve)  present a more homogeneous pattern with lower 
standard errors compared to the allogeneic transplants. The glycaemic values are always extremely 
significant in this time gap (*** p<0.001 days 30, 45, 60, 70 vs. day 0). In contrast, the curve relative to 
the allogeneic transplants (blue line) shows greater standard error, there are only two statistically 
significant values compared with the curve relative to the syngeneic transplants (*** p<0.001 days 30, 45 
vs. day 0), and a return to diabetic values from day 60 onwards is shown. It should be noted that the last 
two time points give a very significant difference between the two curves (** p<0.01 days 60,70 syn vs. 
days 60, 70 allo). Glycaemic pattern of syngeneic 700 IE + 500,000 EPC in the long-term (B). The 
animals that received a syngeneic transplant were  observed over a long period of time  (up to 6 months). 
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The pattern shows a homogeneous decrease during the overall extension time. After 70 days from 
transplantation, the curve continues to show extremely significant values also at 90, 120 and 180 days 
(*** p<0.001 vs. day 0), with low standard error values. The blood glycaemic levels remain largely under 
the threshold level (300 mg/dl) and even under 200 mg/dl for long-term extension time.   
 
 
4.2.4 Portal vein transplantation of 700 IE + 500,000 MSCs 
 
Our previous work showed the immunomodulatory effect of MSCs when 
these cells were administered via the tail vein into a syngeneic rat model of 
transplantation either in a single (150,000 MSCs) or multiple dose (3x150,000 MSCs, 
days 0, 2, 4  after transplant)241. These two types of treatment improved the glycaemic 
levels in diabetic animals up to 20 days after transplantation. In addition, it was also 
noticed that the efficacy of MSCs is dose–dependent and that the observed treatment 
was effective when the administered dose of the tail vein was triple compared to the 
portal vein dose.  
We therefore decided to perform the syngeneic transplants by increasing the 
dose of MSCs ( 700 IE + 500,000 MSCs) and administering both, islets and MSCs, via 
the portal vein in order to obtain a long lasting effect for the glycaemic levels.  
In figure 24 A it was shown a comparison between the animals transplanted 
with syngeneic 700 IE + 500,000 MSCs via the portal vein (violet line) and the 
corresponding syngeneic 700 IE alone (green line). There was a fast decrease in the 
blood glucose levels of syngeneic 700 IE + 500,000 MSCs transplants compared to 700 
IE alone. The syngeneic transplants, 700 IE + 500,000 MSCs, showed values that 
remain statistically significant in the first 15 days (*** p<0.001 day 3, 5, 7, 15 vs. day 
0).  
The group of animals transplanted with syngeneic 700 IE showed a decrease 
in glycaemic levels in the early post-transplant days, but the values returned to diabetic 
levels even though they show statistically significant points in the first 15 days (** 
p<0.01 day 3 vs. day 0, *** p<0.001 day 5, 7 vs. day 0). 
It should be noted that on the fifteenth day there was a significant difference 
in glycaemic levels between the group transplanted with 700 IE alone and the group 
transplanted with 700 IE + 500,000 MSCs (* p<0.05 day 15 700 IE vs. day 15 700 IE + 
500,000 MSCs). 
In figure 24 B it was shown the trend of the glucose levels of syngeneic 
transplants with 700 IE + 500,000 MSCs during the overall observation time (up to 75 
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days). The glycaemic levels were under the diabetic threshold value (300 mg/dl), even 
under 200 mg/dl, and remained so until the end of the observation period. By comparing 
these values with the glycaemic levels at day 0 they proved to be extremely significant 
(*** p<0.001 day 30, 45, 60, 72 vs. day 0).  
 
 
A       B 
 
Figure 24. Transplantation with syngeneic 700 IE + 500,000 MSCs. Comparison between syngeneic 
700 IE and 700 IE + 500,000 MSCs via the portal vein (A) Islets alone show a return to diabetic values 
within 15 days after transplantation, even though the trend shows statistically significant points (green 
line, ** p<0.01 day 3 vs. day 0, *** p<0.001 days 5, 7 vs. day 0). The syngeneic transplants with 700 IE 
+ 500,000 MSCs via the portal vein (violet line) show a considerable decrease linked to continuous 
extremely significant values within the first 15 days after the transplant (*** p<0.001 days 3, 5, 7, 15 vs. 
day 0). There is a significant difference on the fifteenth day between syngeneic 700 IE alone and 
syngeneic 700 IE + 500,000 MSCs transplant (* p<0.05 day 15 700 IE vs. day 15 700 IE + 500,000 
MSCs). Glycaemic pattern of syngeneic 700 IE + 500,000 MSCs in the long-term (B). The pattern shows 
a decrease up to 75 days. The curve continues to show extremely significant values (*** p<0.001 day 30, 
45, 60 and 72 vs. day 0), with low standard error values. The blood glycaemic levels remain largely under 
the threshold level (300 mg/dl) and even under 200 mg/dl in the long-term.   
 
4.2.5 Comparison between syngeneic portal vein transplantation of 700 IE + 500,000 
EPCs and 700 IE + 500,000 MSCs  
 
The curves relative to the 700 IE plus cell therapies (500,000 EPCs or 
500,000 MSCs), both syngeneic, were represented in figure 25 A.  
The  curve relative to 700 IE + 500,000 MSCs transplant (violet line) 
showed a faster decreasing trend and lower levels of glycaemic values compared with 
700 IE + 500,000 EPCs (red line), but both curves showed extremely significant values 
during the first 15 days from transplantation (*** p<0.001 day 3, 5, 7, 15 vs. day 0 
either for MSCs or EPCs treatment). 
 92
Glycaemic levels for both curves remained low until 70 days after 
transplantation with similar patterns. Levels continued to remain significantly high in 
both curves even after 15 days up until the end of the monitoring time (*** p<0.001 day 
30, 45, 60, 70 vs. day 0 either for MSC or EPC treatment), (figure 25 B). 
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Figure 25. Comparison between syngeneic 700 IE + 500,000 EPCs and syngeneic 700 IE + 500,000 
MSCs transplants. Comparison between cells treatment in the first 15 days from transplant (A) The 
syngeneic curve of 700 IE + 500,000 EPCs (red line) shows a considerable decrease, linked to extremely 
significant values, within the first 15 days after the transplant (*** p<0.001 days 3, 5, 7, 15 vs. day 0). 
The trend relative to the transplants 700 IE + 500,000 MSCs (violet line) shows  a more homogeneous 
decrease than the previous one, with a slight increase after 7 days. Even for the MSC curve, many time 
points are extremely significant (*** p<0.001 days 3, 5, 7, 15 vs. day 0). Comparison between cells 
treatment in the long-term (B) After 15 days the two curves appear analogous in their trend of glycaemic 
levels over a period of up to 70 days. Indeed, both curves remain under the diabetic threshold and with the 
same significant time points (*** p<0.001 days 30, 45, 60, 70 vs. day 0 for both curves, syngeneic and 
allogeneic). 
 
 
4.2.6 Intra peritoneal Glucose Tolerance Test (IPGTT) 
 
In order to assess the glucose metabolism of the animals a series of intra 
peritoneal glucose tolerance tests (IPGTT) were performed in all transplanted groups 
and compared with healthy and diabetic reference curves. 
A comparison between the disposal of the glucose 15 days after 
transplantation for animals that received syngeneic 700 IE, allogeneic 500,000 EPCs 
alone and syngeneic 700 IE + 500,000 EPCs was shown in figure 26 A.  
The curve relative to healthy animals showed a decline in blood glucose 
starting 15 minutes after the D-glucose injection, while the curve relative to the 
syngeneic 700 IE + 500,000 EPCs transplants showed a higher increase in blood 
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glucose up to 30 minutes after the glucose administration followed by a decrease to 
non-diabetic values.  
The curve relative to syngeneic 700 IE + 500,000 EPCs transplants showed a 
very significant value at 120 minutes when compared with diabetic values (green line, 
** p<0.01 120 min syngeneic vs. 120 min diabetic), while for the healthy animals an 
extremely significant level was observed (red line, *** p<0.001 120 min healthy vs. 120 
min diabetic).  
The curves relative to allogeneic 500,000 EPCs alone (orange line) and 
syngeneic 700 IE (pink line) transplants showed higher values than the previous ones in 
the disposal of the glucose; both curves showed no significance levels compared to the 
diabetic curve.  
Since we observed a fast glucose metabolism for the syngeneic 700 IE + 
500,000 EPCs transplants 15 days after transplantation, we decided to compare the 
disposal of the glucose for that group at different time points compared to healthy 
animals (15, 30, 90 days after the transplant), figure 26 B.  
The trends in glucose disposal of these transplants were very similar in that, 
they showed a similar decreasing pattern up to 90 days after transplantation which could 
be correlated with the long-term control of glycaemic levels for this group. The curve 
relative to the syngeneic transplants at 15 days post transplantation showed levels of 
significance at 30 and 60 minutes compared to the time of D-glucose injection (** 
p<0.01 t=30 vs. t=0; * p<0.05 t=60 vs. t=0).  
Moreover, the trend relative to the syngeneic transplant at 30 days post 
transplant showed only one value of significance at 30 minutes compared to the zero 
point of its curve (** p<0.01 t=30 vs. t=0).  
Finally, the syngeneic transplant curve at 90 days post transplant showed 
many statistically significant values at 15, 30, 60, 90 minutes compared to the time of 
D-glucose injection (* p<0.05 t=15 vs. t=0; *** p<0.001 t=30, 60 vs. t=0; ** p<0.01 
t=90 vs. t=0). None of the curves relative to the syngeneic 700 IE + 500,000 EPCs at 
different time points showed any levels of statistical significance within the three 
curves. 
The curve relative to the animals which received allogeneic 700 IE + 
500,000 EPCs transplants was shown in figure 26 C. The curve showed a disposal of the 
glucose 15 days after transplantation with higher values than the syngeneic one, but 
there were very significant levels at 120 minutes when compared with diabetic values 
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(light blue line, ** p<0.01 120 min allogeneic vs. 120 min diabetic), while for the 
healthy animals an extremely significant level was observed (red line, *** p<0.001 120 
min healthy vs. 120 min diabetic).  
The curves relative to allogeneic 500,000 EPCs alone (orange line) and 
allogeneic 700 IE (violet line) transplants showed values even higher than the previous 
ones in the disposal of the glucose; both curves showed no significant levels compared 
to the diabetic curve.  
A comparison of the glucose metabolism between the syngeneic and the 
allogeneic trends of 700 IE + 500,000 EPCs transplants at 15 days after transplantation 
compared to healthy animals was shown in figure 26 D. The values of the syngeneic 
curve indeed showed lower levels of blood glucose compared to the allogeneic animals 
but the allogeneic curve showed extremely significant levels compared to healthy ones 
(green line, *** p<0.001 120 min syngeneic vs. 120 min healthy). 
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Figure 26. Intra peritoneal glucose tolerance tests in several groups of transplanted animals. 
Comparison of syngeneic transplant curves 15 days after transplantation (A). Disposal of the glucose for 
animals receiving syngeneic 700 IE (pink line), allogeneic 500,000 EPCs alone (orange line) and 
syngeneic 700 IE + 500,000 EPCs (green line) in comparison with healthy (red line) and diabetic animals 
(blue line). Significance of the groups: syngeneic 700 IE + 500,000 EPCs ** p<0.01 120 min syngeneic 
vs. 120 min diabetic; healthy animals *** p<0.001 120 min healthy vs. 120 min diabetic. Comparison of 
syngeneic transplant curves at different time points (B). Disposal of the glucose at 15, 30, 90 days after 
transplantation for animals receiving syngeneic 700 IE + 500,000 EPCs. Significance of the syngeneic 
700 IE + 500,000 EPCs transplants at different time points: 15 days (green line) ** p<0.01 t=30 vs. t=0; * 
p<0.05 t=60 vs. t=0; 30 days (grey line ** p<0.01 t=30 vs. t=0; 90 days (brown line) * p<0.05 t=15 vs. 
t=0; *** p<0.001 t=30, 60 vs. t=0; ** p<0.01 t=90 vs. t=0. Comparison of allogeneic transplant curves 
15 days after transplantation (C). Disposal of the glucose for animals receiving allogeneic 700 IE (violet 
line), allogeneic 500,000 EPCs alone (orange line) and allogeneic 700 IE + 500,000 EPCs (light blue line) 
in comparison with healthy (red line) and diabetic animals (blue line). Significance of the groups: 
allogeneic 700 IE + 500,000 EPCs transplants ** p<0.01 120 min allogeneic vs. 120 min diabetic; healthy 
animals *** p<0.001 120 min healthy vs. 120 min diabetic. Comparison of syngeneic and allogeneic 700 
IE + 500,000 EPCs transplants 15 days after transplantation (D). Disposal of the glucose for animals 
receiving syngeneic 700 IE + 500,000 EPCs (green line) and allogeneic 700 IE + 500,000 EPCs (light 
blue line) in comparison with healthy animals (red line). Significance of the groups: *** p<0.001 120 min 
syngeneic 700 IE + 500,000 EPCs vs. 120 min healthy controls. 
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4.3 Ex vivo experiments 
4.3.1 Gene expression in liver tissues in IE and IE + EPCs transplantation by RT-PCR 
 
Quantitative RT-PCR was used to measure the expression levels of VEGF-
A, SDF-1, ANG-1 and PECAM-1 in ex vivo liver tissues of animals transplanted with 
syngeneic 700 IE (IE) and 700 IE + 500,000 EPCs (IE+EPCs). 
Expression levels were analyzed at different time points after transplantation 
(7, 15, 30 and 180 days after the transplant) and compared to the expression of the liver 
of healthy controls. 
mRNA expression levels for VEGF-A were found to reach a peak at 15 days 
after transplantation, followed by a decrease at 30 days for both groups (IE and 
IE+EPCs) with a further decrease for IE+EPCs group at 180 days post-transplant (figure 
27 A) (* p<0.05 day 7 IE+EPCs vs. HEALTHY; *** p<0.001 day 15 IE vs. 
HEALTHY; ** p<0.01 day 15 IE+EPCs vs. HEALTHY). 
Similar results were found also for ANG-1 where the IE group showed an 
increase its values of relative mRNA expression up to 15 days after the transplant and 
then slightly decreased at 30 days post-transplant. On the other hand, the IE+EPCs 
group showed an increase in ANG-1 from very low levels to levels comparable to 
healthy ones in the first 15 days, then the gene expression slightly decreased at 30 days 
and even more at 180 days after the transplant, (figure 27 B), (** p<0.01 day 7 
IE+EPCs vs. HEALTHY; ** p<0.01 day 7 IE vs. HEALTHY; * p<0.5 day 15 IE vs. 
IE+EPCs; * p<0.5 day 30 IE vs. IE+EPCs).  
It is worth noting that the expression levels of animals transplanted with 700 
IE alone at 15 and 30 days after transplant remained high and also that both groups, 
either 700 IE or 700 IE + EPCs, showed a similar decreasing pattern from 15 to 30 days 
from transplant, as showed by the comparison of the ratio between the gene expression 
value at 15 and 30 days (1.21 IE vs. 1.36 IE+EPC).   
The expression level of PECAM-1 revealed a different pattern for the two 
groups: the relative level of mRNA expression in IE alone markedly increased between 
days 7 and 15 post-transplantation and then decreased at 30 days. In the IE+EPCs 
group, instead, there were no relevant changes in the expression levels from days 7 to 
15, but a further decrease at 30 days was observed (figure 27 C), (* p<0.5 day 7 
IE+EPCs vs. HEALTHY; * p<0.5 day 15 IE vs. HEALTHY; * p<0.5 day 15 IE vs. 
IE+EPCs; ** p<0.01 day 30 IE vs. IE+EPCs). 
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The SDF-1 pattern is different from all other gene expressions: from 7 to 30 
days after the transplant a reduced expression in IE alone was observed, while levels of 
SDF-1 relative to the IE+EPCs group revealed a small increase from 7 to 15 days post-
transplant followed by a decrease at 30 days (figure 27 D).  
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Figure 27. Gene expression. VEGF-A (A), ANG-1 (B), PECAM-1 (C), SDF-1 (D) expression in liver 
tissues of animals transplanted with IE and IE+EPCs at different time points. 
 
4.3.2 Comparison of gene expression in liver tissues in IE + MSCs and IE + EPCs 
transplantation by RT-PCR 
A comparison of the expression levels of VEGF-A, SDF-1, ANG-1 and 
PECAM-1 between ex vivo liver tissues of animals transplanted with syngeneic 700 IE 
+ 500,000 EPCs (IE+EPCs) and 700 IE + 500,000 MSCs (IE+MSCs) was investigated 
by quantitative RT-PCR. Genes were studied at different time points after 
transplantation. 
The VEGF-A gene expression showed a peak at 15 days after the transplant 
for the IE+EPCs group followed by a relevant decrease at 60 days; for the IE+MSCs, 
however, a decrease between days 7 and 60 post-transplant was observed, but the levels 
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remained at healthy values (figure 28 A), (* p<0.5 day 15 IE+EPCs vs. HEALTHY; * 
p<0.5 day 15 IE+MSCs vs. IE+EPCs).    
In figure 28 B the ANG-1 gene had a peak for the IE+EPCs group at 15 days 
(the level was comparable to the healthy control), whereas for IE+MSCs, the gene 
slightly increased up to 60 days post transplantation (** p<0.01 day 7 IE+EPCs vs. 
HEALTHY; ** p<0.01 day 7 IE+MSCs vs. HEALTHY; * p<0.5 day 15 IE+MSCs vs. 
HEALTHY; * p<0.5 day 15 IE+MSCs vs. IE+EPCs; * p<0.5 day 60 IE+MSCs vs. 
HEALTHY; * p<0.5 day 60 IE+EPCs vs. HEALTHY).  
For both IE+EPCs and IE+MSCs groups there was an increase in PECAM-1 gene 
expression compared to the healthy animals; all the values remained comparable during 
the overall monitoring time (figure 28 C), (** p<0.01 day 7 IE+EPCs vs. HEALTHY; 
** p<0.01 day 7 IE+MSCs vs. HEALTHY).  
Finally, the SDF-1 gene for the IE+MSCs group showed a relevant decrease 
from 7 to 15 days with a marked growth at 60 days post-transplant, whereas no relevant 
changes in the trend of the IE+EPCs group was observed for this gene expression 
during the observation time (figure 28 D), (* p<0.5 day 7 IE+MSCs vs. HEALTHY; * 
p<0.01 day 7 IE+MSCs vs. IE+EPCs; *** p<0.01 day 60 IE+MSCs vs. HEALTHY; 
*** p<0.01 day 60 IE+EPCs vs. IE+MSCs).     
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A      B 
 
C      D 
 
 
Figure 28. Comparison of gene expression. Comparison between gene expression of VEGF-A (A), 
ANG-1 (B), PECAM-1 (C), SDF-1 (D) in liver tissues of animals transplanted with IE, IE+EPCs and 
IE+MSCs at different time points. 
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5. DISCUSSION 
 
Pancreatic islet transplantation is one of the actual promising and available 
therapies for treating type 1 diabetes mellitus. Islet transplantation is indeed considered 
a promising strategy for the treatment of diabetes mainly in young patients and children 
with any evident insurgence of severe complications (when possibility of whole organ 
transplant has been discarded)46. Compared to the whole organ transplant and to 
exogenous insulin treatment, islet transplantation offers various advantages such as the 
a relatively simple surgical procedure (mini-invasive surgery), and consequently low 
post-operative risks and low morbidity; it is also possible to culture islets or 
cryopreserve them. 
The protocols used to handle pancreatic islets for reducing their 
immunogenicity revealed that a short time of culture is adequate. Furthermore, for this 
purpose it is probable that  a manipulation of pre-operative intervention of the islets is 
required (i.e. islet encapsulation by means of particular membranes to avoid or delay the 
aggressive effect from the host’s immune system – immunoisolation)242. These 
procedures allow to optimize the recipient’s conditioning, with a consequent easier 
tolerance induction and less risk of rejection. In addition, the requirement for 
immunosuppressive drugs treatment is low45.  
Human islet transplantation is carried out under local anaesthetic with a low 
infusion of islets through the insertion of a catheter into the portal vein at the 
transhepatic percutaneous site243. Due to the mini-invasive surgery, there is a reduction 
in complications and it enables glycaemic levels to re-establish themselves thereby 
avoiding any further hypoglycaemic crisis and irreversible pancreatic injuries45. 
Moreover, the islet vasculature cultured in vitro and their subsequent 
transplantation can dedifferentiate or degenerate from its original architecture. In 
addition, the days immediately after islet transplantation are critical since this process is 
characterized by substantial islet cell dysfunction and β-cells death – a more 
pronounced characteristic in diabetic recipients55. The blood flow of the transplanted 
islets seems to be lower in diabetic recipients244 and could be caused by an altered 
regulation rather than a defect in the revascularization process93. 
Several aspects need to be overcome in order to introduce the practice of 
islet transplantation as a routine therapy. Besides the limits that derive from the 
isolation and purification of the islets, significant graft survival is required as well as the 
 101
avoidance of side effects linked to immunosuppressive drugs, which have a toxic effect 
on transplanted β cells and other organs and tissues33. 
In addition, in the immediate post-transplant period islets are subjected to 
inflammatory reactions which are either acute or chronic: macrophages (or Kuppfer’s 
cells) that reside in the vascular hepatic sinusoid (where islets mainly tend to establish 
themselves) can exert harmful effects on the graft through the secretion of pro-
inflammatory cytokines, digestive enzymes, reactive oxygen species245. Furthermore, it 
must be considered that a fatal, acute or chronic rejection can occur and severely impair 
the graft outcomes.  
The aim of this project was the study of MSCs as an alternative therapy to 
the conventional immunosuppression in pancreatic islet transplantation given their well-
known immunomodulatory functions for reducing acute rejection62. We also studied the 
role of EPCs in overcoming the critical vascularization within the pancreatic islets once 
they have been isolated and purified. 
In our model, both types of cells (either MSCs or EPCs) were injected 
together with pancreatic islets and syngeneic and allogeneic transplants were performed 
in order to re-establish normoglycaemic levels in the long-term in chemically induced 
diabetic rats. 
Indeed, the reduced functionality of the islets in the long-term was 
considered as crucial for the β-cell engraftment after transplantation into the vascular 
site74. 
As previously reported by Longoni et al.359, transplants performed with 
syngeneic and allogeneic 700 IE in the portal vein of diabetic animals have shown a 
decrease in glycaemic values within the first 15 days after the transplant for both types 
of models.  
We observed that the curve relative to the syngeneic transplants (700 IE L-L) 
showed a decrease and then a slight growth towards diabetic levels, but the animals 
showed better maintenance of glucose and their significant levels by the twelfth day 
post transplant.  
The trend of the allogeneic transplants (700 IE WF-L) showed a fast 
decrease in the early post transplant period but returned to diabetic values after just 9 
days from transplant with significant levels only in the first week after the 
transplantation (figure 20). 
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These data reflect the key role of the implantation site for pancreatic islets 
because the intraportal site is considered to provoke a reduction in islet function, mostly 
in the long-term74. 
As shown by Jacobson, cell therapies based on the use of MSCs and 
pancreatic islets resulted in a lower grade of rejection compared to an islet-alone 
transplant when both were administered under the kidney capsule and they prolonged 
islet survival in order to obtain better control of blood glucose levels212. Moreover, 
MSCs were reported to enhance the survival of insulin-secreting β-cells when they were 
injected together with islets into the omental pouch215. 
The protective role exerted by MSCs in islet transplantation was further 
assessed by a model of a transplant via the portal vein in diabetic-induced animals; it 
was indeed reported that the islets transplanted with MSCs maintained a normal, 
undisturbed structure, whereas islet-alone transplants appeared fragmented218. 
On the basis of data obtained in our previous work, in which islets were 
injected in the portal vein of diabetic animals which simultaneously received a triple 
dose of MSCs in the tail vein (at days 0, 2, 4 after the transplant)241, we decided to 
perform a pancreatic islet transplantation in a syngeneic model by increasing the dose of 
MSCs administered via the portal vein in order to prolong the blood glucose control. 
We observed that the MSCs were able to improve glucose level control during the 
overall monitoring time (figure 24), as confirmed also by recent studies on a model of 
islet and MSC co-transplant246.  
As shown by Rackham, the transplantation of MSCs together with IE under 
the kidney capsule improved the ability of islets to reverse hyperglycaemia in 
streptozotocin-treated rodents246. 
Moreover, several papers demonstrated also that the immunosuppressive 
properties of MSCs highlighted the allogeneic islet survival after transplantation by 
secreting cytokines or metalloproteinases247. In the syngeneic islet transplantation 
model, the advantageous role of co-transplanted MSCs could be due to trophic factors 
on islet cell viability and function213. 
Since the altered vascularization of pancreatic islets in impaired tissue is 
considered to be fundamental for the success of islet transplantation, we decided to 
improve islet revascularization in our experimental model by exploiting the angiogeneic 
properties of EPCs. An impaired endothelium can be repaired by being partially covered 
by resident endothelial cells together with the contribution of circulating EPCs118. The 
 103
typical properties of EPCs could also heal the endothelial damage and form new blood 
vessels in ischaemic tissues. Studies on experimentally induced mechanical endothelial 
damage showed that EPCs were able to repair the vessel wall, re-establishing 
anatomical and functional endothelial integrity125. Several studies showed the minor 
recruitment of EPCs in vivo at sites of ischemia in diabetic models and also that 
reendothelization is less likely to take place in the presence of EPC dysfunction160. 
On the basis of evidence reported in literature, in this project we firstly 
evaluated the effect of the administration of EPCs alone on blood glucose levels in an 
allogeneic transplant model via the portal vein of diabetic-induced Lewis rats. The 
resulting curve showed a non-homogeneous trend, so that within the first week after 
transplant the animals returned to diabetic values. The significant levels were observed 
only at days 3 and 7 after the transplant, exactly in correspondence with a decrease in 
the glucose values due to remaining β-cell function, (figure 21). The EPCs alone were 
effective in the early post-transplant days as confirmed by low glycaemic levels. We 
hypothesized that this temporary effect was due to an improvement in the 
vascularization of the residual pancreatic islets. In addition, this was not enough to re-
establish the complete functionality and glucose homeostasis for the entire observation 
time, because the temporary effect was not associated with a recovery of islet mass. 
Furthermore, we decided to combine the effect of EPCs with pancreatic 
islets: both a syngeneic and allogeneic model of a marginal mass of 700 IE was 
transplanted together with 500,000 EPCs in the portal vein of diabetic animals, (figure 
22). Both groups reached normoglycaemic levels; the animals which received 
allogeneic therapy were found to re-establish levels under the diabetic threshold over a 
period of up to 75 days, (figure 23 A), whereas the syngeneic ones remained 
normoglycaemic during the overall monitoring time (6 months after the transplant), 
(figure 23 B). Thus, we hypothesized that the animals transplanted with allogeneic cell 
therapy were reported to become normoglycaemic only up to 75 days because they 
could incur allograft rejection due to a lack in the immunosuppressive treatment.  
These data were in accordance with the results obtained with IPGTT 
performed on syngeneic transplanted animals, while the allogeneic ones were reported 
to have a worse trend in the curve of IPGTT as also confirmed by glycaemic levels, 
(figure 26). These data need to be further confirmed by histological analysis on hepatic 
and pancreatic tissues. 
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We subsequently compared the group of animals transplanted with 700 IE + 
500,000 EPCs and 700 IE + 500,000 MSCs: a similar decreasing pattern was observed 
for both groups and they were also shown to be under the diabetic threshold value until 
the end of the monitoring time, (figure 25). We did not observe relevant statistically 
significant differences between the two curves. 
Our data based on the detection of glycaemic levels appeared to improve the 
vascularization of the graft. This was further investigated by ex vivo experiments on 
hepatic samples of transplanted animals by quantitative evaluation of gene expression 
with a molecular biology assay.  
Since the angiogenesis issue is a very complex argument to deal with 
regarding endothelial proliferation and differentiation, we found that a fine series of 
mechanisms are involved in the regulation of angiogenesis and a molecular control of 
endothelial cell behaviour during cell migration and proliferation for the blood vessel 
formation is equally implicated229. 
To this aim, the most important gene involved in the regulation of blood 
vessel sprouting during development, growth and disease, is VEGF, also known as the 
vascular permeability factor. In particular, VEGF-A is the main member of a family of 
homodimeric glycoproteins whose expression is positively regulated by hypoxia248.  
Our data showed that syngeneic transplants with 700 IE caused a marked 
increase in the VEGF-A level in liver tissues of animals in the first 15 days after 
transplantation, (figure 27 A). This could be due to the incomplete vascular network 
formation and a partial recovery in functionality when the islets alone are transplanted 
via the portal vein in diabetic recipients. In agreement with data demonstrating that 
VEGF in the diabetic group at 5, 7, and 14 days showed a marked gene expression, the 
vascularization of transplanted islets is delayed by the presence of hyperglycemia, 
deriving from an increase in local oxygen consumption103. 
In comparison with animals treated with syngeneic 700 IE, a similar pattern 
for VEGF-A gene expression was observed for 700 IE + 500,000 EPCs. A peak was 
observed at 15 days also for this group with a consequent and relevant decrease up to 
healthy values, and even under the healthy threshold for the overall monitoring time (up 
to 6 months), (figure 27 A). 
We found that 15 days after transplantation the EPCs were able to regulate 
the revascularization process already begun by the islets; this result was correlated with 
the decreased level of VEGF-A expression compared to the islets alone at the same time 
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point. This could be in accordance with other in vivo studies showing that diabetes leads 
to an inability to mobilize EPCs from the bone marrow to the peripheral circulation in 
response to ischaemia and that post ischaemic angiogenesis was significantly 
compromised in diabetic animals compared to non-diabetic ones157. However, we found 
a full recovery in the glycaemic pattern in the long-term for the syngeneic 700 IE + 
500,000 EPC group, thus we supposed that our observed trend in VEGF-A expression 
for the long period was consistent with these data. 
The analysis of VEGF-A expression for the syngeneic 700 IE + 500,000 
MSC group revealed no relevant changes, (figure 28 A).  
Another key gene involved in the cellular mechanism of angiogenesis is 
ANG-1, which has been extensively reviewed by many authors249. ANG-1 which is 
produced by mural cells, can stabilize vessels and promote pericytes adhesion by 
making them leakage-resistant and by tightening endothelial junctions to maintain of 
endothelial cell quiescence250. This gene is also able to promote basement membrane 
deposition and vascular maintenance249. Recently, this traditional aspect of the 
angiopoietin family was changed by a study of the Jeansson’s group who demonstrated 
that ANG-1 was not necessary in the quiescent mature vasculature but had a protective 
factor in the regulation of responses to tissue injury and microvascular disease in 
diabetes251. In this context Brissova found that the importance of revascularization after 
islet transplantation was expressed by a reciprocal endocrine cell–endothelial cell 
communication, since early differentiating endocrine cells produced angiogenic factors 
also including ANG-1106. 
We observed an increase in ANG-1 expression in the syngeneic 700 IE alone 
group at 15 days after transplantation, the critical time point for islet revascularization; 
at 30 days after the transplant, we observed only a slight decrease in the genetic value of 
ANG-1, thus suggesting the weak ability of islets to tighten and mature blood vessels in 
a diabetic environment, (figure 27 B). 
A similar pattern was observed for the syngeneic group transplanted with 
700 IE + 500,000 EPCs where a decreasing trend occurred from 15 days after the 
transplant up to the end of the monitoring time of 6 months, (figure 27 B). Gene levels 
concerning this group were much lower than the previous ones, indicating that the 
revascularization was supposed to be completed for animals treated with EPCs.  
As previously studied by Ward et al.252, a marked expression in ANG-1 in 
the liver of developing mice induced vascular remodelling effects including hepatic 
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arterial sprouting and enlargement, while in adult mice a reduced effect was observed in 
liver with regard to vessel size. The data we obtained were in line with that of 
Jeansson’s group because ANG-1 was essential for vascular development, while it was 
negligible in quiescent vessels251; furthermore, the developing vasculature did not 
involve the regulation of pericyte recruitment or smooth muscle cell investment, as 
previously believed, thus conferring a more protective role for ANG-1. 
In the group of animals treated with 700 IE + 500,000 MSCs we observed an 
irrelevant increase in ANG-1 expression from 7 to 60 days post-transplant, (figure 28 
B). This could be correlated with a study by Zacharek and colleagues who observed that 
treating strokes with MSCs promoted angiogenesis and vascular stabilization by 
increasing Ang1/Tie2 expression and up-regulating ischemic brain occludin 
expression228. This evidence needs to be carefully understood also because another 
disease model was used, thus gene expression could vary according to the observed 
tissue101. 
We also investigated the function of PECAM-1 whose expression is 
restricted to cells of the vascular system, namely platelets, monocytes, neutrophils, 
selected T cells and endothelial cells. It was suggested that this gene was involved in 
transendothelial migration of neutrophils, monocytes, and natural killer cells in both in 
vivo and in vitro models, since transmigration and inflammation could be significantly 
reduced when antibodies directed against PECAM-1 were used253. 
In our transplant groups we observed a marked signal for PECAM-1 in the 
liver tissue of animals transplanted with 700 IE alone increasing from 7 to 15 days after 
surgery and a further reduction to low levels at 30 days. In the group of animals which 
received 700 IE + 500,000 EPCs, a different pattern was observed: from 7 to 15 days 
after the transplant the trend of the gene was similar, at 30 days there was a decline, 
while at the end of the monitoring time of 6 months a slight increase appeared again, 
(figure 27 C). Moreover, in the group of animals treated with 700 IE + 500,000 MSCs 
we found no great deviations in PECAM-1 expression during the overall monitoring 
time in our ex vivo liver tissues, (figure 28 C). 
We therefore hypothesized that the role of transmigration attributed to 
PECAM-1 had to be considered for animals receiving 700 IE alone where a peak was 
observed at 15 days post-transplant, whereas we did not find a marked regulation of this 
gene for the other groups, either 700 IE + 500,000 EPCs or 700 IE + 500,000 MSCs. 
We speculated that this trend could be due to a lack of migration of cells such as 
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neutrophils, monocytes, and natural killer cells because we administered either EPCs or 
MSCs exogenously, so no relevant changes in the expression profile of this gene were 
observed. 
Finally, we observed the gene expression of SDF-1 which has an important 
role in the regulation of a variety of cellular functions of endothelial progenitor cells, 
such as cell migration, proliferation, survival and angiogenesis. SDF-1 was also found 
to exert its essential role in stem cell homing toward the ischemic/hypoxic myocardium 
by recruiting the progenitor cells that express its cognate receptor, CXC chemokine 
receptor 4 (CXCR4)254. 
Since β cell injury was recently found to induce SDF-1 production254, we 
observed, in accordance with this evidence, that a peak at 7 days post transplant was 
detected in the group of animals transplanted with 700 IE alone, due to islet damage in 
the first few days and a recruitment of endothelial cells, (figure 27 D). 
Moreover, in the syngeneic group of 700 IE + 500,000 EPCs transplants a 
lower value for SDF-1 gene expression was observed when compared to the previous 
one. Since the effect of SDF-1 on neovascularization appears to enhance the recruitment 
and incorporation of transplanted EPCs255, we supposed that a steady state in the gene 
expression up to 15 days, followed by a decrease and a further increase, could be due to 
a recovery in the neovascularization and also to an improvement in β cell function for 
animals who received this cell therapy, (figure 27 D).  
Finally, we observed that animals treated with syngeneic 700 IE + 500,000 
MSCs showed reduced SDF-1 expression from 7 to 15 days after the transplant, 
whereas at the end of the monitoring time a relevant increase in the gene was observed 
again, (figure 28 D). The increased expression of this gene at 60 days after 
transplantation could be in accordance with an in vivo study on a rat model of 
myocardial infarction256 which showed that MSCs differentiated into endothelial cells 
were due to the presence of SDF-1α and also that an over-expression of SDF-1α can 
produce effective angiogenesis with a resulting prevention of progressive heart 
dysfunction after a myocardial infarction.  
On the basis of our results, we hypothesized that EPCs were able to re-
establish the impaired vascularization of transplanted islets by inducing a full recovery 
in islet functionality in the syngeneic transplant model. In the allogeneic model we 
observed a control of islet function up to 75 days post-transplant, thereby confirming 
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the outcome of allorejection as we did not administer either pharmacological or MSC-
based immunosuppressive treatment. 
Furthermore, from our molecular biological results we observed that the 
critical time point for the revascularization was the fifteenth day when the angiogenic 
and revascularizing genes were observed (VEGF-A, ANG-1, PECAM-1). After this 
time point there was a decrease in all gene expressions, except for SDF-1 which was 
reported to have a different pattern.  
In the group transplanted with 700 IE alone, a relevant expression in VEGF-
A, ANG-1 and PECAM-1 genes was observed which could be compared to β-cell 
injury; this cell therapy needs to be further vascularized.  
On the other hand, the group of animals transplanted with 700 IE + 500,000 
EPCs showed a lower expression in the same genes when we compared the same time 
points with 700 IE alone. In addition, angiogenic gene expression for the 700 IE + 
500,000 EPC group showed that at the end of the monitoring time the levels were 
comparable to the healthy control. These results suggested that EPCs were considered to 
be able to regulate the process of islet revascularization.  
The SDF-1 gene for the 700 IE alone showed a peak at 7 days post-
transplant, indicating that a β cell injury occurred and endothelial recruitment was 
necessary. The same gene expressed by animals treated with the 700 IE + 500,000 EPCs 
group was found to be different, because the levels were close to the healthy control. 
We suggested that endothelial recruitment did not occur, also because the endothelial 
cells were administered exogenously. 
With regard to cell therapy administered with 700 IE + 500,000 MSCs via 
the portal vein, we observed that all genes, except for SDF-1, were down-regulated 
when compared to IE and EPCs treatment. We speculated that after this down-
regulation MSCs started their revascularization function. This could be in accordance 
with the immunomodulatory property of MSCs as observed in the treatment of 
GVHD62. 
The only gene which was not down-regulated for MSCs treatment was SDF-
1, which was reported to have a peak value in the first few days after the transplant and 
to recruit endothelial cells; it then decreased and finally a high value was observed 
again. This could be explained with the hypothesis that a differentiation process is 
ongoing, as confirmed by Tang in a model of myocardial infarction256.  
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Nevertheless, all these data need to be confirmed by further histological 
evaluation that is currently in progress in collaboration with the University of Cagliari. 
The histological analysis will supply evidence of the supposed presence of lymphocytic 
infiltration, as a supporting hypothesis of rejection outcome in allogeneic models, or 
vascularization which could occur due to a supposed new vessel formation in grafted 
tissues in syngeneic models. 
Furthermore, experiments on vessel density, the hypoxia and the VEGF 
receptors assessment as well as the detection of soluble factors released by either EPCs 
or MSCs in our pancreatic islet transplants, will be investigated. In addition, we are also 
examining, by means of biochemical in vitro assays, our hypothesis that MSCs begin 
the revascularization process and finally differentiate into endothelium.     
In conclusion, in this project we observed for the first time that EPCs were 
able to revascularize pancreatic islets and that these cells could improve syngeneic graft 
survival up to the complete healing of diabetic patients (6 months), as shown also by 
complete glycaemic recovery and consistent intraperitoneal glucose tests. Thus, EPCs 
could act through a regulatory mechanism as shown by their angiogenic gene 
expression. 
Furthermore, we suppose that the cell therapy based on MSCs showed that 
these cells were able to improve graft vascularization as supported by glycaemic values. 
Nevertheless, the mechanism of action of MSCs could be different to that of EPCs 
because MSCs exerted their ability to be immunomodulatory. We hypothesized that 
MSCs could be considered as the beginner of a new vascularization process and that 
they completed their action with a final differentiation development.    
In order to have a more complete spectrum of our evidence, further studies 
need to be carried out with regard to the allogeneic model such as the administration of 
immunosuppressive treatment, either pharmacological or MSC-based, to obtain a full 
recovery of pancreatic islet function. 
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